Canopy Growth (CGC) 10-Q 9 Feb 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2021	Feb. 08, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Registrant Name	Canopy Growth Corporation
Entity Central Index Key	0001737927
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		394,170,916
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common shares, no par value
Trading Symbol	CGC
Security Exchange Name	NASDAQ
Entity File Number	001-38496
Entity Incorporation, State or Country Code	Z4
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	1 Hershey Drive
Entity Address, City or Town	Smiths Falls
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	K7A 0A8
City Area Code	855
Local Phone Number	558-9333
Document Quarterly Report	true
Document Transition Report	false

Condensed Interim Consolidated

Condensed Interim Consolidated Balance Sheets (Unaudited) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Current assets:
Cash and cash equivalents	$ 615,146	$ 1,154,653
Short-term investments	807,884	1,144,563
Restricted short-term investments	12,208	11,332
Amounts receivable, net	100,901	92,435
Inventory	365,750	367,979
Prepaid expenses and other assets	86,267	67,232
Total current assets	1,988,156	2,838,194
Other financial assets	898,497	708,167
Property, plant and equipment	1,080,179	1,074,537
Intangible assets	338,753	308,167
Goodwill	1,988,250	1,889,354
Other assets	15,195	5,061
Total assets	6,309,030	6,823,480
Current liabilities:
Accounts payable	67,837	67,262
Other accrued expenses and liabilities	76,007	100,813
Current portion of long-term debt	15,702	9,827
Other liabilities	79,700	106,428
Total current liabilities	239,246	284,330
Long-term debt	1,494,665	1,573,136
Deferred income tax liabilities	27,366	21,379
Other liabilities	195,618	107,240
Total liabilities	2,097,386	3,201,660
Commitments and contingencies
Redeemable noncontrolling interest	68,700	135,300
Canopy Growth Corporation shareholders' equity:
Common shares - $nil par value; Authorized - unlimited number of shares; Issued - 394,157,998 shares and 382,875,179 shares, respectively	7,478,834	7,168,557
Additional paid-in capital	2,482,372	2,415,650
Accumulated other comprehensive loss	(26,727)	(34,240)
Deficit	(5,795,721)	(6,068,156)
Total Canopy Growth Corporation shareholders' equity	4,138,758	3,481,811
Noncontrolling interests	4,186	4,709
Total shareholders' equity	4,142,944	3,486,520
Total liabilities and shareholders' equity	6,309,030	6,823,480
Acreage
Current liabilities:
Liability arising from Acreage Arrangement	103,000	600,000
Warrant
Current liabilities:
Derivative liability	$ 37,491	$ 615,575

Condensed Interim Consolidate_2

Condensed Interim Consolidated Balance Sheets (Parenthetical) (Unaudited) - shares	Dec. 31, 2021	Mar. 31, 2021
Statement Of Financial Position [Abstract]
Common stock, shares issued	394,157,998	382,875,179

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Operations and Comprehensive (Loss) Income (Unaudited) - CAD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue		$ 155,024	$ 169,907	$ 456,095	$ 439,823
Excise taxes		14,052	17,379	47,540	41,613
Net revenue		140,972	152,528	408,555	398,210
Cost of goods sold		130,882	127,943	442,367	341,050
Gross margin		10,090	24,585	(33,812)	57,160
Operating expenses
Selling, general and administrative expenses		116,835	144,078	355,165	426,723
Share-based compensation		6,777	19,963	35,856	72,632
Expected credit losses on financial assets and related charges			13,735		108,480
Asset impairment and restructuring costs		36,439	400,422	128,198	459,579
Total operating expenses		160,051	578,198	519,219	1,067,414
Operating loss		(149,961)	(553,613)	(553,031)	(1,010,254)
Loss from equity method investments			(671)	(100)	(40,851)
Other income (expense), net		34,282	(290,567)	810,769	(21,106)
(Loss) income before income taxes		(115,679)	(844,851)	257,638	(1,072,211)
Income tax recovery		183	15,600	490	18,086
Net (loss) income		(115,496)	(829,251)	258,128	(1,054,125)
Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest		(6,571)	75,129	(14,307)	(9,183)
Net (loss) income attributable to Canopy Growth Corporation		$ (108,925)	$ (904,380)	$ 272,435	$ (1,044,942)
Basic (loss) earnings per share		$ (0.28)	$ (2.43)	$ 0.70	$ (2.83)
Basic weighted average common shares outstanding		393,818,282	372,908,767	390,423,083	369,418,037
Diluted (loss) earnings per share	[1]	$ (0.28)	$ (2.43)	$ 0.43	$ (2.83)
Diluted weighted average common shares outstanding		393,818,282	372,908,767	410,986,802	369,418,037
Comprehensive income (loss):
Net (loss) income		$ (115,496)	$ (829,251)	$ 258,128	$ (1,054,125)
Other comprehensive income (loss), net of income tax effect
Fair value changes of own credit risk of financial liabilities		16,200	(30,090)	26,280	(82,560)
Foreign currency translation		(15,479)	(45,809)	(18,767)	(110,932)
Total other comprehensive income (loss), net of income tax effect		721	(75,899)	7,513	(193,492)
Comprehensive income (loss)		(114,775)	(905,150)	265,641	(1,247,617)
Comprehensive income (loss) attributable to noncontrolling interests and redeemable noncontrolling interest		(6,571)	75,129	(14,307)	(9,183)
Comprehensive income (loss) attributable to Canopy Growth Corporation		$ (108,204)	$ (980,279)	$ 279,948	$ (1,238,434)
[1]	In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Shareholder's Equity (Unaudited) - CAD ($) $ in Thousands	Total	Common Shares	Additional Paid-in capitalShare-based Reserve	Additional Paid-in capitalWarrant	Additional Paid-in capitalOwnership Changes	Additional Paid-in capital Redeemable Noncontrolling Interest	Accumulated Other Comprehensive Income (Loss)	Deficit	Noncontrolling Interests
Beginning balance at Mar. 31, 2020	$ 5,108,120	$ 6,373,544	$ 517,741	$ 2,638,951	$ (501,403)	$ (40,134)	$ 220,899	$ (4,323,236)	$ 221,758
Other issuances of common shares and warrants	7,945	35,666	(27,721)
Exercise of warrants	244,990	315,256		(70,266)
Exercise of Omnibus Plan stock options	37,999	61,167	(23,168)
Share-based compensation	69,243		69,243
Issuance and vesting of restricted share units		2,092	(2,092)
Changes in redeemable noncontrolling interest	(41,350)					(51,230)			9,880
Ownership changes relating to noncontrolling interests	5,092				(243)				5,335
Comprehensive income (loss)	(1,247,617)						(193,492)	(1,044,942)	(9,183)
Ending balance at Dec. 31, 2020	4,184,422	6,787,725	534,003	2,568,685	(501,646)	(91,364)	27,407	(5,368,178)	227,790
Beginning balance at Mar. 31, 2021	3,486,520	7,168,557	480,786	2,568,438	(512,340)	(121,234)	(34,240)	(6,068,156)	4,709
Other issuances of common shares and warrants	266,448	296,574	(30,126)
Replacement equity instruments from the acquisition of Supreme Cannabis	18,916		5,566	13,350
Exercise of Omnibus Plan stock options	5,455	8,690	(3,235)
Share-based compensation	35,172		35,172
Issuance and vesting of restricted share units		5,013	(5,013)
Changes in redeemable noncontrolling interest	66,600					53,500			13,100
Ownership changes relating to noncontrolling interests	684								684
Redemption of redeemable noncontrolling interest	(2,492)				2,617	(5,109)
Comprehensive income (loss)	265,641						7,513	272,435	(14,307)
Ending balance at Dec. 31, 2021	$ 4,142,944	$ 7,478,834	$ 483,150	$ 2,581,788	$ (509,723)	$ (72,843)	$ (26,727)	$ (5,795,721)	$ 4,186

Condensed Interim Consolidate_5

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net (loss) income	$ 258,128	$ (1,054,125)
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable	4,083	(12,507)
Prepaid expenses and other assets	6,702	(4,353)
Inventory	28,818	(2,937)
Accounts payable and accrued liabilities	(30,764)	13,094
Other, including non-cash foreign currency	(25,713)	(57,808)
Net cash used in operating activities	(419,125)	(367,899)
Depreciation of property, plant and equipment	56,467	54,625
Amortization of intangible assets	27,462	43,565
Share of loss on equity method investments	100	40,851
Share-based compensation	35,856	72,632
Asset impairment and restructuring costs	113,250	422,610
Expected credit losses on financial assets and related charges		108,480
Income tax recovery	(490)	(18,086)
Non-cash fair value adjustments	(893,024)	26,060
Cash flows from investing activities:
Purchases of and deposits on property, plant and equipment	(36,620)	(137,977)
Purchases of intangible assets	(4,564)	(7,238)
Proceeds on sale of property, plant and equipment	25,660	30,921
Proceeds on sale of intangible assets		18,337
(Purchases) redemption of short-term investments	340,218	(83,612)
Net cash proceeds on sale of subsidiaries	10,324
Sale of equity method investments		7,000
Investment in other financial assets	(374,414)	(34,236)
Investment in Acreage Arrangement		(49,849)
Loan advanced to Acreage Hempco		(66,995)
Net cash outflow on acquisition of subsidiaries	(14,947)
Other investing activities	(16,759)	(5,269)
Net cash used in investing activities	(71,102)	(328,918)
Cash flows from financing activities:
Proceeds from issuance of common shares and warrants	1,460
Proceeds from exercise of stock options	5,455	37,999
Proceeds from exercise of warrants		244,990
Repayment of long-term debt	(50,217)	(13,271)
Other financing activities	(3,036)	(578)
Net cash (used in) provided by financing activities	(46,338)	269,140
Effect of exchange rate changes on cash and cash equivalents	(2,942)	(50,539)
Net decrease in cash and cash equivalents	(539,507)	(478,216)
Cash and cash equivalents, beginning of period	1,154,653	1,303,176
Cash and cash equivalents, end of period	615,146	824,960
Cash received during the period:
Income taxes	993	4,176
Interest	10,844	19,078
Cash paid during the period:
Income taxes	2,641	20,376
Interest	83,968	12,886
Noncash investing and financing activities
Additions to property, plant and equipment	$ (5,145)	$ 16,220

Description of Business

Description of Business	9 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1 Canopy Growth Corporation is a publicly traded corporation, incorporated in Canada, with its head office located at 1 Hershey Drive, Smiths Falls, Ontario. References herein to “Canopy Growth” or “the Company” refer to Canopy Growth Corporation and its subsidiaries. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult recreational and medical purposes under a portfolio of distinct brands in Canada pursuant to the Cannabis Act

Basis of Presentation

Basis of Presentation	9 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	2 These condensed interim consolidated financial statements have been presented in Canadian dollars and are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Canopy Growth has determined that the Canadian dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of our operations across multiple geographies, the majority of our operations are conducted in Canadian dollars and our financial results are prepared and reviewed internally by management in Canadian dollars. Our condensed interim consolidated financial statements, and the financial information contained herein, are reported in thousands of Canadian dollars, except share and per share amounts or as otherwise stated. Certain information and footnote disclosures normally included in the audited annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted or condensed. These condensed interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 (the “Annual Report”) and have been prepared on a basis consistent with the accounting policies as described in the Annual Report. These condensed interim consolidated financial statements are unaudited and reflect adjustments (consisting of normal recurring adjustments) that are, in the opinion of management, necessary to provide a fair statement of results for the interim periods in accordance with U.S. GAAP. The results reported in these condensed interim consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for an entire fiscal year. The policies set out below are consistently applied to all periods presented, unless otherwise noted. Principles of consolidation The accompanying condensed interim consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. Information on the Company’s subsidiaries with noncontrolling interests is included in Note 20. Use of estimates The preparation of these condensed interim consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates. New accounting policies Recently Adopted Accounting Pronouncements Income Taxes In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted ASU 2019-12 as of April 1, 2021. There was no material impact of adopting ASU 2019-12 on the condensed interim consolidated financial statements. Investments-Equity Securities In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) Accounting Guidance not yet adopted Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted after December 15, 2020.

Asset Impairment and Restructur

Asset Impairment and Restructuring Costs	9 Months Ended
	Dec. 31, 2021
Restructuring And Related Activities [Abstract]
Asset Impairment and Restructuring Costs	3. ASSET IMPAIRMENT AND RESTRUCTURING COSTS In the three months ended June 30, 2021, the Company recorded charges related to operational changes resulting from the continuing strategic review of its business as a result of recent acquisition activities, which resulted in the closure of its Niagara-on-the-Lake, Ontario and Langley, British Columbia facilities. Additionally, the Company recognized costs associated with the closure of previously-identified Canadian production facilities in December 2020. In the three months ended September 30, 2021, the Company recognized incremental costs associated with the closure of certain of its Canadian production facilities in December 2020. In the three months ended December 31, 2021, the Company recorded charges primarily associated with adjustments related to changes in the estimated fair value of certain of the Company’s Canadian sites that were closed in December 2020. As a result, in the three and nine months ended December 31, 2021, the Company recognized asset impairment and restructuring costs of $36,439 and $128,198, respectively, primarily representing the difference between the net book value of the associated long-lived assets and their estimated fair value.

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Dec. 31, 2021
Cash And Cash Equivalents [Abstract]
Cash and Cash Equivalents	4. CASH AND CASH EQUIVALENTS The components of cash and cash equivalents are as follows: December 31, March 31, 2021 2021 Cash $ 421,675 $ 436,588 Cash equivalents 193,471 718,065 $ 615,146 $ 1,154,653

Short-term Investments

Short-term Investments	9 Months Ended
	Dec. 31, 2021
Short Term Investments [Abstract]
Short-term Investments	5. SHORT-TERM INVESTMENTS The components of short-term investments are as follows: December 31, March 31, 2021 2021 Term deposits $ 354,745 $ 463,824 Asset-backed securities 63,197 16,342 Government securities 21,026 136,620 Commercial paper and other 368,916 527,777 $ 807,884 $ 1,144,563 The amortized cost of short-term investments at December 31, 2021 is $809,722 (March 31, 2021 – $1,145,364).

Amounts Receivable, Net

Amounts Receivable, Net	9 Months Ended
	Dec. 31, 2021
Receivables [Abstract]
Amounts Receivable, Net	6. AMOUNTS RECEIVABLE, NET The components of amounts receivable, net are as follows: December 31, March 31, 2021 2021 Accounts receivable, net $ 82,554 $ 67,106 Indirect taxes receivable 6,553 8,281 Interest receivable 5,372 5,140 Other receivables 6,422 11,908 $ 100,901 $ 92,435 Included in the accounts receivable, net balance at December 31, 2021 is an allowance for doubtful accounts of $2,037 (March 31, 2021 – $1,411)

Inventory

Inventory	9 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventory	7. INVENTORY The components of inventory are as follows: December 31, March 31, 2021 2021 Raw materials, packaging supplies and consumables $ 55,741 $ 55,554 Work in progress 166,425 223,652 Finished goods 143,584 88,773 $ 365,750 $ 367,979 In the three and nine months ended December 31, 2021, the Company recorded write-downs related to inventory in cost of goods sold of $11,811 and $104,662 (three and nine months ended December 31, 2020 – $23,836 and $48,167).

Prepaid Expenses and Other Asse

Prepaid Expenses and Other Assets	9 Months Ended
	Dec. 31, 2021
Prepaid Expense And Other Assets Current [Abstract]
Prepaid Expenses and Other Assets	8. PREPAID EXPENSES AND OTHER ASSETS The components of prepaid expenses and other assets are as follows: December 31, March 31, 2021 2021 Prepaid expenses $ 31,292 $ 28,349 Deposits 19,200 18,316 Prepaid inventory 1,244 1,496 Other assets 34,531 19,071 $ 86,267 $ 67,232

Other Financial Assets

Other Financial Assets	9 Months Ended
	Dec. 31, 2021
Schedule Of Investments [Abstract]
Other Financial Assets	9. OTHER FINANCIAL ASSETS The following table outlines changes in other financial assets. Additional details on how the fair value of significant investments is calculated are included in Note 21. Foreign Exercise of Balance at currency options / Balance at March 31, Fair value translation Interest disposal December 31, Entity Instrument 2021 Additions changes adjustments income of shares 2021 TerrAscend Exchangeable Shares Exchangeable shares $ 385,000 $ - $ (166,000 ) $ - $ - $ - $ 219,000 TerrAscend Canada - October 2019 Term loan / debenture 10,240 - 750 - - - 10,990 TerrAscend Canada - March 2020 Term loan / debenture 56,330 - 550 - - - 56,880 Arise Bioscience Term loan / debenture 13,077 - 921 105 - - 14,103 TerrAscend - October 2019 Warrants 17,250 - (10,770 ) - - - 6,480 TerrAscend - March 2020 Warrants 152,910 - (73,830 ) - - - 79,080 TerrAscend - December 2020 Warrants 13,240 - (6,920 ) - - - 6,320 TerrAscend Option 10,600 - (4,600 ) - - - 6,000 Wana Option - 442,227 - 9,472 - - 451,699 Acreage Hempco 1 Debenture 27,448 - 4,023 197 (3,867 ) - 27,801 Other - at fair value through net income (loss) Various 14,887 6,457 (8,070 ) (138 ) - (92 ) 13,044 Other - classified as held for investment Loan receivable 7,185 - - - - (85 ) 7,100 $ 708,167 $ 448,684 $ (263,946 ) $ 9,636 $ (3,867 ) $ (177 ) $ 898,497 1 Wana On October 14, 2021, the Company and Mountain High Products, LLC, Wana Wellness, LLC and The Cima Group, LLC (collectively, “Wana” and each, a “Wana Entity”) entered into definitive agreements (the “Wana Agreements”) providing the Company with the right, upon the occurrence or waiver (at the Company’s discretion) of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana, or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”), to acquire 100% of the outstanding membership interests of Wana. Wana manufactures and sells gummies in the U.S. state of Colorado and licenses its intellectual property to partners, who manufacture, distribute, and sell Wana-branded gummies across the United States. The Wana Agreements are structured as three separate option agreements whereby the Company has a call option (the “Call Option”) to acquire 100% of the membership interests in each Wana Entity. As consideration for entering into the Wana Agreements, the Company made an upfront cash payment (the “Upfront Payment”) in the aggregate amount of $368,067 (US$297,500). Upon the Company’s exercise of its right to acquire Wana, the Company will make payments equal to 15% of the fair market value of Wana at the time the options are exercised (the “Call Option Payments”). As additional consideration for the right to acquire Wana, the Company expects to make additional deferred payments (the “Deferred Payments”) in respect of Wana as of the 2.5- and 5-year anniversary of the Upfront Payment, computed based on a pre-determined contractual formula as follows: • Deferred Payment 1: 25% of the amount computed as the estimated fair value of Wana at the 2.5-year anniversary, less (i) the Upfront Payment, (ii) Wana debt, and (iii) certain other deductions; plus Wana cash, all at the 2.5-year anniversary. • Deferred Payment 2: 25% of the amount computed as the estimated fair value of Wana at the 5-year anniversary, less (i) the greater of (a) the Upfront Payment and (b) the estimated fair value of Wana at the 2.5-year anniversary, (ii) Wana debt, and (iii) certain other deductions, all at the 5-year anniversary; plus the difference in Wana cash between the 5-year and 2.5-year anniversaries. Payment of the Deferred Payments is not contingent upon the occurrence or waiver (at the Company’s discretion) of the Triggering Event or the exercise of the Call Option. At the Company’s option, the Call Option Payments and the Deferred Payments may be satisfied in cash, common shares or a combination thereof at the Company’s sole discretion. Until such time as the Company exercises its right to acquire Wana, the Company will have no economic or voting interest in Wana, the Company will not control Wana, and the Company and Wana will continue to operate independently. Upon initial recognition, the Company estimated the fair value of the Wana financial instrument to be $442,227, consisting of (i) the Upfront Payment as noted above; and (ii) the present value of the estimated Deferred Payments, totaling $74,160 (see Note 15). The Wana financial instrument, in effect, represents an option to purchase 100% of Wana for a payment equal to 15% of Wana’s fair market value at the time the option is exercised. There was no change in the estimated fair value of the Wana financial instrument from initial recognition to December 31, 2021. Any subsequent changes in estimated fair value will be recognized in net income (loss). See Note 21 for additional details on how the fair value of the Wana financial instrument is calculated on a recurring basis.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	10. PROPERTY, PLANT AND EQUIPMENT The components of property, plant and equipment are as follows: December 31, March 31, 2021 2021 Buildings and greenhouses $ 820,863 $ 651,166 Production and warehouse equipment 204,790 216,925 Leasehold improvements 86,307 106,837 Office and lab equipment 32,093 30,546 Land 23,410 34,747 Computer equipment 23,097 26,431 Right-of-use-assets Buildings and greenhouses 99,355 100,517 Production and warehouse equipment 182 530 Assets in process 25,496 129,428 1,315,593 1,297,127 Less: Accumulated depreciation (235,414 ) (222,590 ) $ 1,080,179 $ 1,074,537 Depreciation expense included in cost of goods sold for the three and nine months ended December 31, 2021 is $13,813 and $38,663, respectively (three and nine months ended December 31, 2020 – $10,955 and $40,190, respectively). Depreciation expense included in selling, general and administrative expenses for the three and nine months ended December 31, 2021 is $5,546 and $17,804, respectively (three and nine months ended December 31, 2020 – $7,297 and $14,435, respectively).

Intangible Assets

Intangible Assets	9 Months Ended
	Dec. 31, 2021
Intangible Assets Net Excluding Goodwill [Abstract]
Intangible Assets	11. INTANGIBLE ASSETS The components of intangible assets are as follows: December 31, 2021 March 31, 2021 Gross Net Gross Net Carrying Carrying Carrying Carrying Amount Amount Amount Amount Finite lived intangible assets Intellectual property $ 209,650 $ 157,206 $ 212,100 $ 168,655 Distribution channel 76,963 29,568 73,756 35,176 Software and domain names 30,517 13,855 27,836 18,149 Brands 21,675 8,143 21,812 8,894 Operating licenses 12,400 11,472 - - Amortizable intangibles in process 3,729 3,729 1,952 1,952 Total $ 354,934 $ 223,973 $ 337,456 $ 232,826 Indefinite lived intangible assets Acquired brands $ 104,780 $ 67,341 Operating licenses 10,000 8,000 Total intangible assets $ 338,753 $ 308,167 Amortization expense included in cost of goods sold for the three and nine months ended December 31, 2021 is $19 and $62, respectively ( three and nine months ended December 31, 2020 (three and nine months ended December 31, 2020 – $14,034 and $43,503

Goodwill

Goodwill	9 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	12. GOODWILL The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2020 $ 1,954,471 Foreign currency translation adjustments (65,117 ) Balance, March 31, 2021 $ 1,889,354 Purchase accounting allocations 112,939 Disposal of consolidated entities (5,245 ) Foreign currency translation adjustments (8,798 ) Balance, December 31, 2021 $ 1,988,250

Other Accrued Expenses and Liab

Other Accrued Expenses and Liabilities	9 Months Ended
	Dec. 31, 2021
Accounts Payable And Accrued Liabilities Current [Abstract]
Other Accrued Expenses and Liabilities	13. OTHER ACCRUED EXPENSES AND LIABILITIES The components of other accrued expenses and liabilities are as follows: December 31, March 31, 2021 2021 Employee compensation $ 22,559 $ 47,237 Taxes and government fees 7,684 13,550 Professional fees 7,319 11,544 Other 38,445 28,482 $ 76,007 $ 100,813

Debt

Debt	9 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	14. DEBT The components of debt are as follows: December 31, March 31, Maturity Date 2021 2021 Convertible senior notes at 4.25% interest with semi-annual interest payments July 15, 2023 Principal amount $ 600,000 $ 600,000 Accrued interest 12,042 5,664 Non-credit risk fair value adjustment 9,240 109,710 Credit risk fair value adjustment (54,240 ) (27,960 ) 567,042 687,414 Convertible debentures September 10, 2025 31,689 - Accretion debentures September 10, 2025 7,478 - Credit facility March 18, 2026 901,003 891,677 Other revolving debt facility, loan, and financings 3,155 3,872 1,510,367 1,582,963 Less: current portion (15,702 ) (9,827 ) Long-term portion $ 1,494,665 $ 1,573,136 Credit Facility On March 18, 2021, the Company entered into a credit agreement (the “Credit Agreement”) providing for a five-year, first lien senior secured term loan facility in an aggregate principal amount of US$750,000 (the “Credit Facility”). The Company also has the ability to obtain up to an additional US$500,000 of incremental senior secured debt pursuant to the Credit Agreement. The Credit Facility has no principal payments, matures on March 18, 2026, has a coupon of LIBOR plus 8.50% and is subject to a LIBOR floor of 1.00%. In the event that LIBOR can no longer be adequately ascertained or is no longer available, an alternative rate as permitted under the Credit Agreement will be used. The Company’s obligations under the Credit Facility are guaranteed by material wholly-owned Canadian and U.S. subsidiaries of the Company. The Credit Facility is secured by substantially all of these assets, including material real property, of the borrowers and each of the guarantors. The Credit Agreement contains representations and warranties, and affirmative and negative covenants, including a financial covenant requiring minimum liquidity of US$200,000 at the end of each fiscal quarter. The proceeds from the Credit Facility were $ 893,160 , and the carrying amount is reflected net of financing costs. Convertible Notes On June 20, 2018, the Company issued convertible senior notes (the “Notes”) with an aggregate principal amount of $600,000. The Notes bear interest at a rate of 4.25% per annum, payable semi-annually on January 15th and July 15th of each year commencing from January 15, 2019. The Notes will mature on July 15, 2023. The Notes are subordinated in right of payment to any existing and future senior indebtedness, including any indebtedness under the revolving debt facility with FCC (as defined below). The Notes will rank senior in right of payment to any future subordinated borrowings. The Notes are effectively junior to any secured indebtedness and the Notes are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries. Holders of the Notes may convert the Notes at their option at any time from January 15, 2023 to the maturity date. The Notes will be convertible, at the holder’s option, at a conversion rate of 20.7577 common shares for every $1 principal amount of Notes (equal to an initial conversion price of approximately $48.18 per common share), subject to adjustments in certain events. In addition, the holder has the right to exercise the conversion option from September 30, 2018 to January 15, 2023, if (i) the market price of the Company common shares for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the 5 business day period after any consecutive 5 trading day period (the “Measurement Period”) in which the trading price per $1 principal amount of the Notes for each trading day in the Measurement Period was less than 98% of the product of the last reported sales price of the Company’s common shares and the conversion rate on each such trading day, (iii) the Notes are called for redemption or (iv) upon occurrence of certain corporate events (a “Fundamental Change”). A Fundamental Change occurred upon completion of the investment by Constellation Brands, Inc. (“CBI”) in the Company in November 2018, and no holders of Notes surrendered any portion of their Notes in connection therewith. The Company may, upon conversion by the holder, elect to settle in either cash, common shares, or a combination of cash and common shares, subject to certain circumstances. Under the terms of the indenture, if a Fundamental Change occurs and a holder elects to convert its Notes from and including on the date of the Fundamental Change up to, and including, the business day immediately prior to the Fundamental Change repurchase date, the Company may be required to increase the conversion rate for the Notes so surrendered for conversion by a number of additional common shares. Prior to July 20, 2021, the Company could not redeem the Notes except in the event of certain changes in Canadian tax law. On or after July 20, 2021, the Company could redeem for cash, subject to certain conditions, any or all of the Notes, at its option, if the last reported sales price of the Company’s common shares for at least 20 trading days during any 30 consecutive trading day period ending within 5 trading days immediately preceding the date on which the Company provides notice of redemption exceeds 130% of the conversion price on each applicable trading day. The Company may also redeem the Notes, if certain tax laws related to Canadian withholding tax change subject to certain further conditions. The redemption of Notes in either case shall be at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. For accounting purposes, the equity conversion feature did not meet the equity classification guidance, therefore the Company elected the fair value option under ASC 825 – Financial Instruments The overall change in fair value of the Notes during the three and nine months ended December 31, 2021, was a decrease of $16,806 and $120,372, respectively (three and nine months ended December 31, 2020, an increase of $105,588 and $177,588, respectively), which included contractual interest of $6,444 and $19,128 (three and nine months ended December 31, 2020, interest of $6,588 and $19,338, respectively). Refer to Note 21 for additional details on how the fair value of the Notes is calculated. Supreme Cannabis Convertible Debentures and Accretion Debentures On October 19, 2018, Supreme Cannabis (as defined below) entered into an indenture with Computershare Trust Company of Canada (the “Trustee”) pursuant to which Supreme Cannabis issued 6.0% senior unsecured convertible debentures (the “Supreme Debentures”) for gross proceeds of $100,000. On September 9, 2020, Supreme Cannabis and the Trustee entered into a supplemental indenture to effect certain amendments to the Supreme Debentures, which included among other things: (i) the cancellation of $63,500 of principal amount of the Supreme Debentures; (ii) an increase in the interest rate to 8% per annum; (iii) the extension of the maturity date to September 10, 2025; and (iv) a reduction in the conversion price to $0.285. In addition, on September 9, 2020, Supreme Cannabis issued new senior unsecured non-convertible debentures (the “Accretion Debentures”). The principal amount began at $nil and accretes at a rate of 11.06% per annum based on the remaining principal amount of the Supreme Debentures of $36,500 to a maximum of $13,500, compounding on a semi-annual basis commencing on September 9, 2020, and ending on September 9, 2023. The Accretion Debentures are payable in cash, but do not bear cash interest and are not convertible into Supreme Shares (as defined below) . The principal amount of the Accretion Debentures will amortize, or be paid, at 1.0% per month over the 24 months prior to maturity. As a result of the Supreme Arrangement (as defined below), the Supreme Debentures remain outstanding as securities of Supreme Cannabis, which, upon conversion will entitle the holder thereof to receive, in lieu of the number of Supreme Shares to which such holder was theretofore entitled, the consideration payable under the Supreme Arrangement that such holder would have been entitled to be issued and receive if, immediately prior to the effective time of the Supreme Arrangement, such holder had been the registered holder of the number of Supreme Shares to which such holder was theretofore entitled. In connection with the Supreme Arrangement, the Company, Supreme Cannabis and the Trustee entered into a supplemental indenture whereby the Company agreed to issue common shares upon conversion of any Supreme Debenture. In addition, the Company may force conversion of the Supreme Debentures outstanding with 30 days’ notice if the daily volume weighted average trading price of the Company’s common shares is greater than $38.59 for any 10 consecutive trading days. The Company, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby the Company agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures. Prior to September 9, 2023, the Supreme Debentures are not redeemable. Beginning on and after September 9, 2023, Supreme Cannabis may from time to time, upon providing 60 days prior written notice to the Trustee, redeem the Convertible Debentures outstanding, provided that the Accretion Debentures have already been redeemed in full. Other revolving debt facility, loans, and financings On August 13, 2019, the Company, through its wholly owned subsidiary, Tweed Inc., entered into a $40,000 revolving debt facility with Farm Credit Canada (“FCC”). The new facility replaces the previous loans with FCC and is secured by the Company’s property in Niagara-on-the-Lake. The extinguishment of $4,912 in previous FCC debt resulted in no gain or loss. The current outstanding balance of the FCC debt facility is $nil (March 31, 2021 – $nil) The revolving debt facility with FCC is secured by a first charge on the properties in Niagara-on-the-Lake, Ontario, a corporate guarantee from the Company, and a general corporate security agreement .

Other Liabilities

Other Liabilities	9 Months Ended
	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Other Liabilities	15. OTHER LIABILITIES The components of other liabilities are as follows: As at December 31, 2021 As at March 31, 2021 Current Long-term Total Current Long-term Total Lease liabilities $ 38,684 $ 104,300 $ 142,984 $ 42,061 $ 94,164 $ 136,225 Acquisition consideration and other investment related liabilities 4,078 83,681 87,759 16,577 7,808 24,385 Refund liability 6,046 - 6,046 6,441 - 6,441 Settlement liabilities and other 30,892 7,637 38,529 41,349 5,268 46,617 $ 79,700 $ 195,618 $ 275,318 $ 106,428 $ 107,240 $ 213,668 On October 14, 2021, upon entering into the Wana Agreements, the Company recognized the present value of the estimated Deferred Payments associated with the Wana financial instrument within acquisition consideration and other investment related liabilities, in the amount of $74,160 (see Note 9).

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interest	9 Months Ended
	Dec. 31, 2021
Temporary Equity Disclosure [Abstract]
Redeemable Noncontrolling Interest	16. REDEEMABLE NONCONTROLLING INTEREST The net changes in the redeemable noncontrolling interests are as follows: Vert Mirabel BioSteel Total As at March 31, 2021 $ 11,500 $ 123,800 $ 135,300 Net loss attributable to redeemable noncontrolling interest (2,401 ) (10,699 ) (13,100 ) Adjustments to redemption amount 2,401 (50,792 ) (48,391 ) Redemption of redeemable noncontrolling interest - (5,109 ) (5,109 ) As at December 31, 2021 $ 11,500 $ 57,200 $ 68,700 Vert Mirabel BioSteel Total As at March 31, 2020 $ 20,250 $ 49,500 $ 69,750 Net loss attributable to redeemable noncontrolling interest (5,593 ) (4,287 ) (9,880 ) Adjustments to redemption amount 5,543 45,687 51,230 As at December 31, 2020 $ 20,200 $ 90,900 $ 111,100

Share Capital

Share Capital	9 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Share Capital	17. SHARE CAPITAL CANOPY GROWTH Authorized An unlimited number of common shares. (i) Equity financings There were no equity financings during the nine months ended December 31, 2021 (nine months ended December 31, 2020 - none). (ii) Other issuances of common shares During the nine months ended December 31, 2021, the Company issued the following shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of shares Share capital Share based reserve Acquisition of Supreme Cannabis 9,013,400 $ 260,668 $ - Completion of acquisition milestones 1,295,285 29,276 (29,721 ) Other issuances 351,252 6,630 (405 ) Total 10,659,937 $ 296,574 $ (30,126 ) During the nine months ended December 31, 2020, the Company issued the following shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of shares Share capital Share based reserve Completion of acquisition milestones 1,149,086 $ 21,531 $ (13,009 ) Other issuances 412,417 14,135 (14,712 ) Total 1,561,503 $ 35,666 $ (27,721 ) (iii) Warrants Number of whole warrants Average exercise price Warrant value Balance outstanding at March 31, 2021 1 127,073,136 $ 58.33 $ 2,568,438 Supreme Cannabis warrants 1,265,742 25.61 13,350 Expiry of warrants (145,831 ) 32.61 - Balance outstanding at December 31, 2021 1 128,193,047 $ 58.04 $ 2,581,788 1 Number of whole warrants Average exercise price Warrant value Balance outstanding at March 31, 2020 1 146,299,443 $ 52.44 $ 2,638,951 Exercise of warrants (18,876,901 ) 12.98 (70,266 ) Expiry of warrants (343,380 ) 41.49 - Balance outstanding at December 31, 2020 1 127,079,162 $ 58.30 $ 2,568,685 1

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	18. SHARE-BASED COMPENSATION CANOPY GROWTH CORPORATION SHARE-BASED COMPENSATION PLAN Canopy Growth's eligible employees participate in a share-based compensation plan as noted below. On September 21, 2020, the Company’s shareholders approved amendments to the Company’s Amended and Restated Omnibus Incentive Plan (as amended and restated, the “Omnibus Plan”) pursuant to which the Company can issue share-based long-term incentives. The Omnibus Plan approved by the shareholders extended the maximum term of each Option (as defined below) to be granted by the Company to ten years from the date of grant rather than six years from the date of grant. On May 27, 2021, the Board of Directors of the Company approved certain amendments to the Omnibus Plan in order to reduce the maximum number of shares available for issuance under the Omnibus Plan from 15% of the issued and outstanding shares to 10% of the issued and outstanding shares from time to time less the number of shares issuable pursuant to other security-based compensation arrangements of the Company. All directors, officers, employees and independent contractors of the Company are eligible to receive awards of common share purchase options (“Options”), restricted share units (“RSUs”), performance share units (“PSUs”), deferred share units, stock appreciation rights, performance awards, or other shares-based awards (collectively, the “Awards”) under the Omnibus Plan. The maximum number of common shares reserved for Awards is 39,415,800 at December 31, 2021. As of December 31, 2021, the only Awards issued have been Options, RSUs and PSUs under the Omnibus Plan. The Omnibus Plan is administered by the Corporate Governance, Compensation and Nominating Committee of the Company (the “CGC&N Committee”) which establishes exercise prices, at not less than the market price at the date of grant, and expiry dates. Options under the Omnibus Plan generally become exercisable in increments with 1/3 Under the Company’s Employee Share Purchase Plan (the “Purchase Plan”) the aggregate number of common shares that may be issued is 600,000, and the maximum number of common shares which may be issued in any one fiscal year shall not exceed 300,000. For the three and nine months ended December 31, 2021, 61,103 common shares were issued under the Purchase Plan. The following is a summary of the changes in the Options outstanding during the nine months ended December 31, 2021: Options issued Weighted average exercise price Balance outstanding at March 31, 2021 17,704,311 $ 36.79 Options granted 2,528,021 17.42 Replacement options issued as a result of the acquisition of Supreme Cannabis 140,159 80.53 Options exercised (421,476 ) 12.65 Options forfeited (2,213,825 ) 39.70 Balance outstanding at December 31, 2021 17,737,190 $ 34.17 The following is a summary of the Options as at December 31, 2021: Options Outstanding Options Exercisable Weighted Average Weighted Average Remaining Remaining Outstanding at Contractual Life Exercisable at Contractual Life Range of Exercise Prices December 31, 2021 (years) December 31, 2021 (years) $0.06 - $24.62 3,789,682 4.31 1,263,512 2.14 $24.63 - $33.53 4,153,283 3.49 2,331,110 2.89 $33.54 - $36.80 3,229,461 2.51 3,229,461 2.51 $36.81 - $42.84 2,857,506 3.19 2,622,583 2.87 $42.85 - $171.54 3,707,258 3.13 2,921,964 3.06 17,737,190 3.36 12,368,630 2.75 At December 31, 2021, the weighted average exercise price of Options outstanding and Options exercisable was $34.17 and $38.05, respectively (March 31, 2021 – $36.79 and $36.97, respectively). The Company recorded $3,696 and $22,038, respectively, in share-based compensation expense related to Options and Purchase Plan shares issued to employees and contractors for the three and nine months ended December 31, 2021 (three and nine months ended December 31, 2020 – $16,663 and $54,516, respectively). The share-based compensation expense for the nine months ended December 31, 2021 includes an amount related to 1,559,413 Options being provided in exchange for services which are subject to performance conditions (for the nine months ended December 31, 2020 – The Company issued replacement options to employees in relation to the acquisition of Supreme Cannabis (Note 26) and during the three and nine months ended December 31, 2021, recorded share-based compensation expense of $nil and $823, respectively. The Company uses the Black-Scholes option pricing model to establish the fair value of Options granted during the three months ended December 31, 2021 and 2020, on their measurement date by applying the following assumptions: December 31, December 31, 2021 2020 Risk-free interest rate 1.21% 0.49% Expected life of options (years) 3 - 5 5 - 7 Expected volatility 75% 73% Expected forfeiture rate 18% 17% Expected dividend yield nil nil Black-Scholes value of each option $7.55 $23.53 Volatility was estimated by using the historical volatility of the Company. The expected life in years represents the period of time that Options granted are expected to be outstanding. The risk-free rate was based on zero coupon Canada government bonds with a remaining term equal to the expected life of the Options. During the nine months ended December 31, 2021, 421,476 Options were exercised ranging in price from $0.06 to $36.34 for gross proceeds of $5,455 (for the nine months ended December 31, 2020 – For the three and nine months ended December 31, 2021, the Company recorded $1,950 and $7,935, respectively, in share-based compensation expense related to RSUs and PSUs (for the three and nine months ended December 31, 2020 – $2,685 and $8,870, respectively). The following is a summary of the changes in the Company’s RSUs and PSUs during the nine months ended December 31, 2021: Number of RSUs and PSUs Balance outstanding at March 31, 2021 753,310 RSUs and PSUs granted 564,150 RSUs and PSUs released (197,316 ) RSUs and PSUs cancelled and forfeited (201,000 ) Balance outstanding at December 31, 2021 919,144 During the three and nine months ended December 31, 2021, the Company recorded $971 and $4,376, respectively, in share-based compensation expense (recovery) related to acquisition milestones (for the three and nine months ended December 31, 2020 – $(21) and $5,857, respectively). During the three and nine months ended December 31, 2021, 419,884 and 1,295,285, common shares, respectively, were released on completion of acquisition milestones (during the three and nine months ended December 31, 2020 – nil and 1,149,086, respectively). At December 31, 2021, there were up to 256,057 common shares to be issued on the completion of acquisition and asset purchase milestones. In certain cases, the number of common shares to be issued is based on the volume weighted average share price at the time the milestones are met. The number of common shares has been estimated assuming the milestones were met at December 31, 2021. The number of common shares excludes common shares that are to be issued on July 4, 2023 to the previous shareholders of Spectrum Colombia S.A.S. and Canindica Capital Ltd. based on the fair market value of the Company’s Latin American business on that date. BioSteel share-based payments On October 1, 2019, the Company purchased 72% of the outstanding shares of BioSteel Sports Nutrition Inc. (“BioSteel”). BioSteel has a stock option plan under which non-transferable options to purchase common shares of BioSteel may be granted to directors, officers, employees, or independent contractors of the BioSteel. As at December 31, 2021, BioSteel had 1,545,300 (March 31, 2021 – 1,581,000) options outstanding which vest in equal tranches over a 5-year period. In determining the amount of share-based compensation related to these options, BioSteel used the Black-Scholes option pricing model to establish the fair value of options on their measurement date. The Company recorded $160 and $684 of share-based compensation expense related to the BioSteel options during the three and nine months ended December 31, 2021, respectively, with a corresponding increase in noncontrolling interest (three and nine months ended December 31, 2020 – $256 and $918, respectively). RIV Capital Inc. (“RIV Capital”) share-based payments For the three and nine months ended December 31, 2020, the Company recorded $381 and $2,471, respectively, in share-based compensation expense related to its former subsidiary, RIV Capital. The Company disposed of its investment in RIV Capital on February 23, 2021.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	19. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income includes the following components: Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2021 $ (28,246 ) $ (5,994 ) $ (34,240 ) Other comprehensive income (loss) (18,767 ) 26,280 7,513 As at December 31, 2021 $ (47,013 ) $ 20,286 $ (26,727 ) Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2020 $ 126,723 $ 94,176 $ 220,899 Other comprehensive loss (110,932 ) (82,560 ) (193,492 ) As at December 31, 2020 $ 15,791 $ 11,616 $ 27,407

Noncontrolling Interests

Noncontrolling Interests	9 Months Ended
	Dec. 31, 2021
Noncontrolling Interest [Abstract]
Noncontrolling Interests	20. NONCONTROLLING INTERESTS The net change in the noncontrolling interests is as follows: Vert Mirabel BioSteel Other non- material interests Total As at March 31, 2021 $ - $ 1,658 $ 3,051 $ 4,709 Comprehensive loss (2,401 ) (10,699 ) (1,207 ) (14,307 ) Net loss attributable to redeemable noncontrolling interest 2,401 10,699 - 13,100 Share-based compensation - 684 - 684 As at December 31, 2021 $ - $ 2,342 $ 1,844 $ 4,186 Canopy Rivers Vert Mirabel BioSteel Other non- material interests Total As at March 31, 2020 $ 211,086 $ 7,132 $ 489 $ 3,051 $ 221,758 Comprehensive loss 4,060 (8,956 ) (4,287 ) - (9,183 ) Net loss attributable to redeemable noncontrolling interest - 5,593 4,287 - 9,880 Share-based compensation 2,471 - 918 - 3,389 Ownership changes 1,521 175 - - 1,696 Warrants 250 - - - 250 As at December 31, 2020 $ 219,388 $ 3,944 $ 1,407 $ 3,051 $ 227,790

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	21. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value measurements are made using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value: • Level 1 – defined as observable inputs such as quoted prices in active markets; • Level 2 – defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and • Level 3 – defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The fair value measurement is categorized in its entirety by reference to its lowest level of significant input. The Company records cash, accounts receivable, interest receivable and accounts payable, and other accrued expenses and liabilities at cost. The carrying values of these instruments approximate their fair value due to their short-term maturities. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. Assets and liabilities recognized or disclosed at fair value on a nonrecurring basis may include items such as property, plant and equipment, goodwill and other intangible assets, equity and other investments and other assets. We determine the fair value of these items using Level 3 inputs, as described in the related sections below. The following table represents our financial assets and liabilities measured at estimated fair value on a recurring basis: Fair value measurement using Quoted prices Significant prices in other Significant active observable unobservable markets inputs inputs (Level 1) (Level 2) (Level 3) Total December 31, 2021 Assets: Short-term investments $ 807,884 $ - $ - $ 807,884 Restricted short-term investments 12,208 - - 12,208 Other financial assets 554 - 890,843 891,397 Liabilities: Convertible senior notes - 567,042 - 567,042 Liability arising from Acreage Arrangement - - 103,000 103,000 Warrant derivative liability - - 37,491 37,491 March 31, 2021 Assets: Short-term investments $ 1,144,563 $ - $ - $ 1,144,563 Restricted short-term investments 11,332 - - 11,332 Other financial assets 254 - 700,728 700,982 Liabilities: Convertible senior notes - 687,414 - 687,414 Liability arising from Acreage Arrangement - - 600,000 600,000 Warrant derivative liability - - 615,575 615,575 The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 2 financial instruments: Financial asset / financial liability Valuation techniques Key inputs Convertible senior notes Convertible note pricing model Quoted prices in over-the-counter broker market The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value Acreage financial instrument Probability weighted expected return model Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value Number of common shares to be issued Increase or decrease in value and number of common shares will result in a decrease or increase in fair value Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Estimated premium on US legalization Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value Control premium Increase or decrease in estimated control premium will result in an increase or decrease in fair value Market access premium Increase or decrease in estimated market access premium will result in an increase or decrease in fair value TerrAscend Exchangeable Shares, TerrAscend Option Put option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Hempco Debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - October 2019, March 2020 Black-Sholes option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value TerrAscend warrants - December 2020 Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Arise Bioscience term loan, TerrAscend Canada term loan - Discounted cash flow Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value October 2019, March 2020 Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Wana financial instrument Monte Carlo simulation model Probability of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Volatility of Wana Increase or decrease in volatility will result in an increase or decrease in fair value Warrant derivative liability Monte Carlo simulation model Volatility of Canopy Growth share price Increase or decrease in volatility will result in an increase or decrease in fair value BioSteel redeemable NCI Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value Vert Mirabel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value During the nine months ended December 31, 2021 and December 31, 2020, there were no transfers of amounts between levels

Revenue

Revenue	9 Months Ended
	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Revenue	22. REVENUE Revenue is dissaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Canadian recreational cannabis net revenue Business-to-business 1 $ 33,282 $ 43,129 $ 117,902 $ 120,286 Business-to-consumer 14,477 20,224 48,473 48,263 47,759 63,353 166,375 168,549 Canadian medical cannabis net revenue 2 12,919 13,947 39,504 41,745 60,678 77,300 205,879 210,294 International and other revenue C 3 9,675 17,642 33,005 46,567 Other 12,624 8,886 32,357 20,543 22,299 26,528 65,362 67,110 Global cannabis net revenue 82,977 103,828 271,241 277,404 Other consumer products Storz & Bickel 25,205 24,147 63,786 63,103 This Works 10,730 10,907 26,308 24,789 BioSteel 16,974 7,348 31,147 14,918 Other 5,086 6,298 16,073 17,996 Other consumer products revenue 57,995 48,700 137,314 120,806 Net revenue $ 140,972 $ 152,528 $ 408,555 $ 398,210 1 – $15,977 and $37,423, respectively). 2 The Company recognizes variable consideration related to estimated future product returns and price adjustments as a reduction of the transaction price at the time revenue for the corresponding product sale is recognized. Net revenue reflects actual returns and variable consideration related to estimated returns and price adjustments in the amount of $1,000 and $4,000 for the three and nine months ended December 31, 2021, respectively (three and nine months ended December 31, 2020 – $3,750 and $10,900, respectively). As of December 31, 2021, the liability for estimated returns and price adjustments was $6,046 (March 31, 2021 – $6,441).

Other Income (Expense), Net

Other Income (Expense), Net	9 Months Ended
	Dec. 31, 2021
Other Income And Expenses [Abstract]
Other Income (Expense), Net	23. OTHER INCOME (EXPENSE), NET Other income (expense), net is dissaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Fair value changes on other financial assets $ (68,666 ) $ 281,359 $ (263,946 ) $ 385,219 Fair value changes on liability arising from Acreage Arrangement 59,000 (303,000 ) 497,000 (249,849 ) Fair value changes on convertible senior notes 606 (75,498 ) 81,342 (107,778 ) Fair value changes on warrant derivative liability 67,282 (193,998 ) 578,084 (93,455 ) Fair value changes on acquisition related contingent consideration and other 712 (3,066 ) 544 39,803 Interest income 1,575 7,310 6,977 19,078 Interest expense (26,408 ) (1,030 ) (77,618 ) (3,708 ) Foreign currency gain (loss) 990 710 2,902 (10,290 ) Loss on disposal of consolidated entity - - (1,653 ) - Other income (expense), net (809 ) (3,354 ) (12,863 ) (126 ) $ 34,282 $ (290,567 ) $ 810,769 $ (21,106 )

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	24. INCOME TAXES There have been no material changes to income tax matters in connection with normal course operations during the nine months ended December 31, 2021. The Company is subject to income tax in numerous jurisdictions with varying income tax rates. During the most recent period ended and the fiscal year to date, there were no material changes to the statutory income tax rates in the taxing jurisdictions where the majority of the Company’s income for tax purposes was earned, or where its temporary differences or losses are expected to be realized or settled. Although statutory income tax rates remain stable, the Company’s effective income tax rate may fluctuate, arising as a result of the Company’s evolving footprint, discrete transactions and other factors that, to the extent material, are disclosed in these financial statements. The Company continues to believe that the amount of unrealized tax benefits appropriately reflects the uncertainty of items that are or may in the future be under discussion, audit, dispute or appeal with a tax authority or which otherwise result in uncertainty in the determination of income for tax purposes. If appropriate, an unrealized tax benefit will be realized in the reporting period in which the Company determines that realization is not in doubt. Where the final determined outcome is different from the Company’s estimate, such difference will impact the Company’s income taxes in the reporting period during which such determination is made.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	25. EARNINGS (LOSS) PER SHARE Basic and diluted earnings (loss) per share are calculated using the following numerators and denominators: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Basic (loss) earnings per share computation Net (loss) income attributable to common shareholders of Canopy Growth $ (108,925 ) $ (904,380 ) $ 272,435 $ (1,044,942 ) Weighted average number of common shares outstanding 393,818,282 372,908,767 390,423,083 369,418,037 Basic (loss) earnings per share $ (0.28 ) $ (2.43 ) $ 0.70 $ (2.83 ) Diluted (loss) earnings per share computation Net (loss) income used in the computation of basic (loss) earnings per share $ (108,925 ) $ (904,380 ) $ 272,435 $ (1,044,942 ) Numerator adjustments for diluted (loss) earnings per share: Adjustment to net loss attributable to noncontrolling interests and redeemable noncontrolling interest - - (13,100 ) - Removal of fair value changes on convertible senior notes - - (81,342 ) - Net (loss) income used in the computation of diluted (loss) earnings per share $ (108,925 ) $ (904,380 ) $ 177,993 $ (1,044,942 ) Weighted average number of common shares outstanding used in the computation of basic (loss) earnings per share 393,818,282 372,908,767 390,423,083 369,418,037 Denominator adjustments for diluted (loss) earnings per share: Dilutive impact of assumed exercise or conversion of: Convertible senior notes - - 12,454,620 - Redeemable noncontrolling interest - - 4,528,898 - Stock options - - 745,700 - Other securities - - 2,834,501 - Weighted average number of common shares for computation of diluted (loss) earnings per share 393,818,282 372,908,767 410,986,802 369,418,037 Diluted (loss) earnings per share 1 $ (0.28 ) $ (2.43 ) $ 0.43 $ (2.83 ) 1

Acquisitions

Acquisitions	9 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Acquisitions	26. ACQUISITIONS The following table summarizes the consolidated balance sheet impact at acquisition of the Company’s business combinations that occurred in the nine months ended December 31, 2021: Ace Supreme Valley Cannabis (i) (ii) Other Total Cash and cash equivalents $ 1,544 $ 41,306 $ 1,227 $ 44,077 Inventory 878 33,426 428 34,732 Other current assets 2,249 15,145 305 17,699 Property, plant and equipment 105 187,407 1,510 189,022 Intangible assets Brands 14,000 24,600 - 38,600 Distribution channel - 3,500 - 3,500 Operating licenses - 12,400 2,000 14,400 Goodwill 39,152 66,524 7,263 112,939 Accounts payable and other accrued expenses and liabilities (1,724 ) (13,056 ) - (14,780 ) Debt and other liabilities - (88,324 ) (1,037 ) (89,361 ) Deferred income tax liabilities (1,899 ) (3,260 ) (540 ) (5,699 ) Net assets acquired $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Consideration paid in shares - 260,668 4,052 264,720 Replacement options - 629 - 629 Replacement warrants - 13,350 - 13,350 Other consideration 2,469 4,937 - 7,406 Total consideration $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Less: Cash and cash equivalents acquired (1,544 ) (41,306 ) (1,227 ) (44,077 ) Net cash outflow (inflow) $ 50,292 $ (41,222 ) $ 5,877 $ 14,947 The table above summarizes the fair value of the consideration given and the fair values assigned to the assets acquired and liabilities assumed for each acquisition. Goodwill arose in these acquisitions because the cost of acquisition included a control premium. In addition, the consideration paid for the combination reflected the benefit of expected revenue growth and future market development. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. None of the goodwill arising on these acquisitions is expected to be deductible in the computation of income for tax purposes. (i) Ace Valley On April 1, 2021, the Company entered into a share purchase agreement (the “AV Share Purchase Agreement”) with Tweed Inc., AV Cannabis Inc. (“Ace Valley”), and the shareholders of Ace Valley (the “AV Vendors”) pursuant to which the Company indirectly acquired 100% of the issued and outstanding shares of Ace Valley for cash consideration of $51,836. Ace Valley is an Ontario-based cannabis brand with a focus on premium, ready-to-enjoy products including vapes, pre-roll joints and gummies. Pursuant to the terms of the AV Share Purchase Agreement, the Company may be required to make certain earn-out payments to the AV Vendors, which may result in an additional cash payment or the issuance of common shares, subject to the fulfillment of certain conditions by April 1, 2023. This represents liability-classified contingent consideration. Management has estimated the fair value of this consideration to be $2,469 by assessing the probability and timing of the fulfillment of the specified conditions and discounting the expected cash outflows to present value. Due to the timing of this acquisition, the purchase price allocation for the acquisition of Ace Valley is provisional. The fair value assigned to the consideration paid, intangible assets and net assets acquired is based on management’s best estimate using the information currently available and may be revised by the Company as additional information is received. (ii) Supreme Cannabis On June 22, 2021, the Company and the Supreme Cannabis Company, Inc. (“Supreme Cannabis”) completed an arrangement (the “Supreme Arrangement”) pursuant to which the Company acquired 100% of the issued and outstanding common shares of Supreme Cannabis (the “Supreme Shares”). Supreme Cannabis is a producer of recreational, wholesale and medical cannabis products, with a diversified portfolio of distinct cannabis companies, products and brands. Pursuant to the Supreme Arrangement, the Company issued 9,013,400 common shares with a fair value on closing of $260,668 and made a cash payment of $84 to former Supreme Cannabis shareholders in consideration for their Supreme Shares. The Company also assumed the obligation to issue 1,265,742 common shares upon the exercise of outstanding warrants of Supreme Cannabis and issued 140,159 replacement options. The fair value of the obligation upon the exercise of the outstanding warrants of Supreme Cannabis was estimated to be $13,350 using a Black-Scholes model. The replacement options’ fair value totaled $1,452, calculated using a Black-Scholes model, of which $629 was included in consideration paid as it related to pre-combination services and the residual $823 fair value was recognized immediately in share-based compensation expense after the completion of the acquisition. On June 22, 2021, Supreme Cannabis had convertible debentures outstanding with a principal amount of $27,045 which were convertible into 94,895,649 Supreme Shares. As a result of the acquisition the conversion feature was adjusted in accordance with an exchange ratio of 0.011659. The fair value of these convertible debentures on June 22, 2021 was estimated to be $36,593, of which $4,937 was allocated to the conversion feature and $31,656 to the debt component. Due to the timing of this acquisition, the purchase price allocation for the acquisition of Supreme Cannabis is provisional. The fair value assigned to the consideration paid, intangible assets and net assets acquired is based on management’s best estimate using the information currently available and may be revised by the Company as additional information is received.

Acreage Arrangement and Amendme

Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants	9 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants	27. ACREAGE ARRANGEMENT AND AMENDMENTS TO CBI INVESTOR RIGHTS AGREEMENT AND WARRANTS Acreage Arrangement On September 23, 2020, the Company and Acreage Holdings, Inc. (“Acreage”) entered into a second amendment (the “Acreage Amending Agreement”) to the arrangement agreement (the “Acreage Arrangement Agreement”) between the Company and Acreage dated April 18, 2019, as amended on May 15, 2019, and implemented an amended and restated plan of arrangement (the “Acreage Amended Arrangement”). The Acreage Amended Arrangement provides for, among other things, the following: • Following the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event and subject to the satisfaction or waiver of the conditions set out in the Acreage Arrangement Agreement (as modified in connection with the Acreage Amending Agreement), Canopy Growth will acquire all of the issued and outstanding Class E subordinated voting shares (the “Fixed Shares”) based on an amended exchange ratio equal to 0.3048 of a common share to be received for each Fixed Share held. The foregoing exchange ratio for the Fixed Shares is subject to adjustment in accordance with the Acreage Amended Arrangement if, among other things, Acreage issues greater than the permitted number of Fixed Shares; • Upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event, Canopy Growth will have the right exercisable for a period of 30 days, to acquire all of the issued and outstanding Class D subordinated voting shares (the “Floating Shares”) for cash or common shares or a combination thereof, in Canopy Growth’s sole discretion at a price equal to the 30-day volume weighted average trading price of the Floating Shares on the Canadian Securities Exchange, subject to a minimum call price of US$6.41 per Floating Share. The foregoing exchange ratio for the Floating Shares is subject to adjustment in accordance with the Acreage Amended Arrangement if Acreage issues greater than the permitted number of Floating Shares. The acquisition of the Floating Shares, if acquired, will take place concurrently with the closing of the acquisition of the Fixed Shares; • Immediately prior to the acquisition of the Fixed Shares, each issued and outstanding Class F multiple voting share will automatically be exchanged for one Fixed Share and thereafter be acquired by Canopy Growth upon the same terms and conditions as the acquisition of the Fixed Shares; • If the occurrence or waiver of the Triggering Event does not occur by September 23, 2030, Canopy Growth’s rights to acquire both the Fixed Shares and the Floating Shares will terminate; • Upon implementation of the Acreage Amended Arrangement, Canopy Growth made a cash payment to the shareholders of Acreage and holders of certain convertible securities in the aggregate amount of US$37,500 ($49,849); and • Acreage is only permitted to issue an aggregate of up to 32,700,000 Fixed Shares and Floating Shares. At December 31, 2021, the right and the obligation (the “Acreage financial instrument”) to acquire the Fixed Shares represents a financial liability of $103,000 (March 31, 2021 – $600,000), as the estimated fair value of the Acreage business is less than the estimated fair value of the consideration to be provided upon the exercise of the Acreage financial instrument. Fair value changes of $59,000 and $497,000 were recognized in other income (expense), net in the three and nine months ended December 31, 2021, respectively (three and nine months ended December 31, 2020 – $(303,000) and $(249,849), respectively) (see Note 23). The fair value determination includes a high degree of subjectivity and judgment, which results in significant estimation uncertainty. See Note 21 for additional details on how the fair value of the Acreage financial instrument is calculated on a recurring basis. From a measurement perspective, the Company has elected the fair value option under ASC 825. In connection with the Acreage Amended Arrangement, on September 23, 2020, an affiliate of the Company advanced US$50,000 ($66,995) to Universal Hemp, LLC, a wholly-owned subsidiary of Acreage (“Acreage Hempco”) pursuant to a secured debenture (“Debenture”). In accordance with the terms of the Debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. The Debenture bears interest at a rate of 6.1% per annum, matures on September 23, 2030, or such earlier date in accordance with the terms of the Debenture, and all interest payments made pursuant to the Debenture are payable in cash by Acreage Hempco. The Debenture is not convertible and is not guaranteed by Acreage. The amount advanced on September 23, 2020 pursuant to the Debenture has been recorded in other financial assets (see Note 9), and the Company has elected the fair value option under ASC 825 (see Note 21). At December 31, 2021, the estimated fair value of the Debenture issued to an affiliate of the Company by Acreage Hempco was $27,801 (March 31, 2021 – $27,448), measured using a discounted cash flow model (see Note 21). Refer to Note 9 for details on fair value changes, foreign currency translation adjustment, and interest received during the nine months ended December 31, 2021. An additional US$50,000 may be advanced pursuant to the Debenture subject to the satisfaction of certain conditions by Acreage Hempco. Amendment to the CBI Investor Rights Agreement and warrants On April 18, 2019, certain wholly-owned subsidiaries of CBI and Canopy Growth entered into a second amended and restated investor rights agreement and a consent agreement. In connection with these agreements, on June 27, 2019, Canopy Growth (i) extended the term of the first tranche of warrants, which allow CBI to acquire 88.5 million additional shares of Canopy Growth for a fixed price of $50.40 per share (the “Tranche A Warrants”), to November 1, 2023; and (ii) replaced the second tranche of warrants with two new tranches of warrants (the “Tranche B Warrants” and the “Tranche C Warrants”) as follows: • the Tranche B Warrants are exercisable to acquire 38.5 million common shares at a price of C$76.68 per common share; and • the Tranche C Warrants are exercisable to acquire 12.8 million common shares at a price equal to the 5-day volume-weighted average price of the common shares immediately prior to exercise. In connection with the Tranche B Warrants and the Tranche C Warrants, Canopy Growth will provide CBI with a share repurchase credit of up to $1.583 billion on the aggregate exercise price of the Tranche B Warrants and Tranche C Warrants in the event that Canopy Growth does not purchase for cancellation the lesser of (i) 27,378,866 common shares; and (ii) common shares with a value of $1.583 billion, during the period commencing on April 18, 2019 and ending on the date that is 24 months after the date that CBI exercises all of the Tranche A Warrants. The share repurchase credit feature is accounted for as a derivative liability, with the fair value continuing to be $nil at December 31, 2021. The modifications to the Tranche A Warrants resulted in them meeting the definition of a derivative instrument under ASC 815 - Derivatives and Hedging The Tranche B Warrants are accounted for as derivative instruments measured at fair value in accordance with ASC 815. At December 31, 2021, the fair value of the warrant derivative liability was $37,491 (March 31, 2021 – $615,575), and fair value changes of $67,282 and $578,084 have been recognized in other income (expense), net in the three and nine months ended December 31, 2021, respectively (three and nine months ended December 31, 2020 – loss of $193,998 and $93,455, respectively) (see Note 23). The fair value determination includes a high degree of subjectivity and judgment, which results in significant estimation uncertainty. See Note 21 for additional details on how the fair value of the warrant derivative liability is calculated on a recurring basis. The Tranche C Warrants are accounted for as derivative instruments, with the fair value continuing to be $nil at December 31, 2021.

Segment Information

Segment Information	9 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment Information	28. SEGMENT INFORMATION Reportable segments The Company is reporting its financial results for the following two operating segments, which are also its reportable segments: (i) global cannabis, and (ii) other consumer products. These segments reflect how the Company’s operations are managed, how the Company’s Chief Executive Officer, who is the chief operating decision maker (“CODM”), allocates resources and evaluates performance, and how the Company’s internal management financial reporting is structured. The Company’s global cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Company’s other consumer products segment comprises the production, distribution and sale of consumer products, including (i) Storz & Bickel vaporizers; (ii) This Works beauty, skincare, wellness and sleep products; (iii) BioSteel sports nutrition beverages, mixes, protein, gum and mints; and (iv) other revenue sources. The Company’s CODM evaluates the performance of these two segments focusing on (i) segment net revenue, and (ii) segment gross margin and gross margin percentage as the measure of segment profit or loss. Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Segmented net revenue Global cannabis $ 82,977 $ 103,828 $ 271,241 $ 277,404 Other consumer products 57,995 48,700 137,314 120,806 $ 140,972 $ 152,528 $ 408,555 $ 398,210 Segmented gross margin: Global cannabis $ (11,209 ) $ 7,394 $ (80,432 ) $ 12,598 Other consumer products 21,299 17,191 46,620 44,562 10,090 24,585 (33,812 ) 57,160 Selling, general and administrative expenses 116,835 144,078 355,165 426,723 Share-based compensation 6,777 19,963 35,856 72,632 Expected credit losses on financial assets and relates charges - 13,735 - 108,480 Asset impairment and restructuring costs 36,439 400,422 128,198 459,579 Operating loss (149,961 ) (553,613 ) (553,031 ) (1,010,254 ) Loss from equity method investments - (671 ) (100 ) (40,851 ) Other income (expense), net 34,282 (290,567 ) 810,769 (21,106 ) Net (loss) income before incomes taxes $ (115,679 ) $ (844,851 ) $ 257,638 $ (1,072,211 ) Asset information by segment is not provided to, or reviewed by, the Company’s CODM as it is not used to make strategic decisions, allocate resources, or assess performance. Entity-wide disclosures Disaggregation of net revenue by geographic area: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Canada $ 78,644 $ 91,060 $ 241,440 $ 243,084 Germany 23,143 31,262 71,619 87,649 United States 22,764 18,141 60,856 40,885 Other 16,421 12,065 34,640 26,592 $ 140,972 $ 152,528 $ 408,555 $ 398,210 Disaggregation of property, plant and equipment by geographic area: December 31, March 31, 2021 2021 Canada $ 876,331 $ 847,678 United States 140,299 143,747 Other 63,549 83,112 $ 1,080,179 $ 1,074,537 For the three months ended December 31, 2021, no customer represented more than 10% of the Company’s net revenue (three months ended December 31, 2020 – one). For the nine months ended December 31, 2021, one customer represented more than 10% of the Company’s net revenue (nine months ended December 31, 2020 – one).

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	29. SUBSEQUENT EVENTS Divestiture of C 3 On December 15, 2021, the Company entered into an agreement to divest all of its interest in C 3 3 3 The divestiture was completed on January 31, 2022, pursuant to which the Company received a cash payment of $ (€ 88,698 ), inclusive of cash, working capital and debt adjustments . The Company will also be entitled to an earnout payment of up to € 42,600 , subject to the achievement of certain milestones by C 3 .

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation The accompanying condensed interim consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. Information on the Company’s subsidiaries with noncontrolling interests is included in Note 20.
Use of estimates	Use of estimates The preparation of these condensed interim consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Income Taxes In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted ASU 2019-12 as of April 1, 2021. There was no material impact of adopting ASU 2019-12 on the condensed interim consolidated financial statements. Investments-Equity Securities In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) Accounting Guidance not yet adopted Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted after December 15, 2020.

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	9 Months Ended
	Dec. 31, 2021
Cash And Cash Equivalents [Abstract]
Components of Cash and Cash Equivalents	The components of cash and cash equivalents are as follows: December 31, March 31, 2021 2021 Cash $ 421,675 $ 436,588 Cash equivalents 193,471 718,065 $ 615,146 $ 1,154,653

Short-term Investments (Tables)

Short-term Investments (Tables)	9 Months Ended
	Dec. 31, 2021
Short Term Investments [Abstract]
Components of Short-term Investments	The components of short-term investments are as follows: December 31, March 31, 2021 2021 Term deposits $ 354,745 $ 463,824 Asset-backed securities 63,197 16,342 Government securities 21,026 136,620 Commercial paper and other 368,916 527,777 $ 807,884 $ 1,144,563

Amounts Receivable, Net (Tables

Amounts Receivable, Net (Tables)	9 Months Ended
	Dec. 31, 2021
Receivables [Abstract]
Components of Amounts Receivable, Net	The components of amounts receivable, net are as follows: December 31, March 31, 2021 2021 Accounts receivable, net $ 82,554 $ 67,106 Indirect taxes receivable 6,553 8,281 Interest receivable 5,372 5,140 Other receivables 6,422 11,908 $ 100,901 $ 92,435

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Components of Inventory	The components of inventory are as follows: December 31, March 31, 2021 2021 Raw materials, packaging supplies and consumables $ 55,741 $ 55,554 Work in progress 166,425 223,652 Finished goods 143,584 88,773 $ 365,750 $ 367,979

Prepaid Expenses and Other As_2

Prepaid Expenses and Other Assets (Tables)	9 Months Ended
	Dec. 31, 2021
Prepaid Expense And Other Assets Current [Abstract]
Components of Prepaid and Other Assets	The components of prepaid expenses and other assets are as follows: December 31, March 31, 2021 2021 Prepaid expenses $ 31,292 $ 28,349 Deposits 19,200 18,316 Prepaid inventory 1,244 1,496 Other assets 34,531 19,071 $ 86,267 $ 67,232

Other Financial Assets (Tables)

Other Financial Assets (Tables)	9 Months Ended
	Dec. 31, 2021
Schedule Of Investments [Abstract]
Summary of Changes in Other Financial Assets	The following table outlines changes in other financial assets. Additional details on how the fair value of significant investments is calculated are included in Note 21. Foreign Exercise of Balance at currency options / Balance at March 31, Fair value translation Interest disposal December 31, Entity Instrument 2021 Additions changes adjustments income of shares 2021 TerrAscend Exchangeable Shares Exchangeable shares $ 385,000 $ - $ (166,000 ) $ - $ - $ - $ 219,000 TerrAscend Canada - October 2019 Term loan / debenture 10,240 - 750 - - - 10,990 TerrAscend Canada - March 2020 Term loan / debenture 56,330 - 550 - - - 56,880 Arise Bioscience Term loan / debenture 13,077 - 921 105 - - 14,103 TerrAscend - October 2019 Warrants 17,250 - (10,770 ) - - - 6,480 TerrAscend - March 2020 Warrants 152,910 - (73,830 ) - - - 79,080 TerrAscend - December 2020 Warrants 13,240 - (6,920 ) - - - 6,320 TerrAscend Option 10,600 - (4,600 ) - - - 6,000 Wana Option - 442,227 - 9,472 - - 451,699 Acreage Hempco 1 Debenture 27,448 - 4,023 197 (3,867 ) - 27,801 Other - at fair value through net income (loss) Various 14,887 6,457 (8,070 ) (138 ) - (92 ) 13,044 Other - classified as held for investment Loan receivable 7,185 - - - - (85 ) 7,100 $ 708,167 $ 448,684 $ (263,946 ) $ 9,636 $ (3,867 ) $ (177 ) $ 898,497 1

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Summary of Expected Useful Life of Property, Plant and Equipment	The components of property, plant and equipment are as follows: December 31, March 31, 2021 2021 Buildings and greenhouses $ 820,863 $ 651,166 Production and warehouse equipment 204,790 216,925 Leasehold improvements 86,307 106,837 Office and lab equipment 32,093 30,546 Land 23,410 34,747 Computer equipment 23,097 26,431 Right-of-use-assets Buildings and greenhouses 99,355 100,517 Production and warehouse equipment 182 530 Assets in process 25,496 129,428 1,315,593 1,297,127 Less: Accumulated depreciation (235,414 ) (222,590 ) $ 1,080,179 $ 1,074,537

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Dec. 31, 2021
Intangible Assets Net Excluding Goodwill [Abstract]
Summary of Components of Intangible Assets	The components of intangible assets are as follows: December 31, 2021 March 31, 2021 Gross Net Gross Net Carrying Carrying Carrying Carrying Amount Amount Amount Amount Finite lived intangible assets Intellectual property $ 209,650 $ 157,206 $ 212,100 $ 168,655 Distribution channel 76,963 29,568 73,756 35,176 Software and domain names 30,517 13,855 27,836 18,149 Brands 21,675 8,143 21,812 8,894 Operating licenses 12,400 11,472 - - Amortizable intangibles in process 3,729 3,729 1,952 1,952 Total $ 354,934 $ 223,973 $ 337,456 $ 232,826 Indefinite lived intangible assets Acquired brands $ 104,780 $ 67,341 Operating licenses 10,000 8,000 Total intangible assets $ 338,753 $ 308,167

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2020 $ 1,954,471 Foreign currency translation adjustments (65,117 ) Balance, March 31, 2021 $ 1,889,354 Purchase accounting allocations 112,939 Disposal of consolidated entities (5,245 ) Foreign currency translation adjustments (8,798 ) Balance, December 31, 2021 $ 1,988,250

Other Accrued Expenses and Li_2

Other Accrued Expenses and Liabilities (Tables)	9 Months Ended
	Dec. 31, 2021
Accounts Payable And Accrued Liabilities Current [Abstract]
Components of Other Accrued Expenses and Liabilities	The components of other accrued expenses and liabilities are as follows: December 31, March 31, 2021 2021 Employee compensation $ 22,559 $ 47,237 Taxes and government fees 7,684 13,550 Professional fees 7,319 11,544 Other 38,445 28,482 $ 76,007 $ 100,813

Debt (Tables)

Debt (Tables)	9 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Summary of Components of Debt	The components of debt are as follows: December 31, March 31, Maturity Date 2021 2021 Convertible senior notes at 4.25% interest with semi-annual interest payments July 15, 2023 Principal amount $ 600,000 $ 600,000 Accrued interest 12,042 5,664 Non-credit risk fair value adjustment 9,240 109,710 Credit risk fair value adjustment (54,240 ) (27,960 ) 567,042 687,414 Convertible debentures September 10, 2025 31,689 - Accretion debentures September 10, 2025 7,478 - Credit facility March 18, 2026 901,003 891,677 Other revolving debt facility, loan, and financings 3,155 3,872 1,510,367 1,582,963 Less: current portion (15,702 ) (9,827 ) Long-term portion $ 1,494,665 $ 1,573,136

Other Liabilities (Tables)

Other Liabilities (Tables)	9 Months Ended
	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Components of Other Liabilities	The components of other liabilities are as follows: As at December 31, 2021 As at March 31, 2021 Current Long-term Total Current Long-term Total Lease liabilities $ 38,684 $ 104,300 $ 142,984 $ 42,061 $ 94,164 $ 136,225 Acquisition consideration and other investment related liabilities 4,078 83,681 87,759 16,577 7,808 24,385 Refund liability 6,046 - 6,046 6,441 - 6,441 Settlement liabilities and other 30,892 7,637 38,529 41,349 5,268 46,617 $ 79,700 $ 195,618 $ 275,318 $ 106,428 $ 107,240 $ 213,668 On October 14, 2021, upon entering into the Wana Agreements, the Company recognized the present value of the estimated Deferred Payments associated with the Wana financial instrument within acquisition consideration and other investment related liabilities, in the amount of $74,160 (see Note 9).

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interest (Tables)	9 Months Ended
	Dec. 31, 2021
Temporary Equity Disclosure [Abstract]
Summary of Net Change in Redeemable Noncontrolling Interests	The net changes in the redeemable noncontrolling interests are as follows: Vert Mirabel BioSteel Total As at March 31, 2021 $ 11,500 $ 123,800 $ 135,300 Net loss attributable to redeemable noncontrolling interest (2,401 ) (10,699 ) (13,100 ) Adjustments to redemption amount 2,401 (50,792 ) (48,391 ) Redemption of redeemable noncontrolling interest - (5,109 ) (5,109 ) As at December 31, 2021 $ 11,500 $ 57,200 $ 68,700 Vert Mirabel BioSteel Total As at March 31, 2020 $ 20,250 $ 49,500 $ 69,750 Net loss attributable to redeemable noncontrolling interest (5,593 ) (4,287 ) (9,880 ) Adjustments to redemption amount 5,543 45,687 51,230 As at December 31, 2020 $ 20,200 $ 90,900 $ 111,100

Share Capital (Tables)

Share Capital (Tables)	9 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Summary of Issuances of Stock Other	During the nine months ended December 31, 2021, the Company issued the following shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of shares Share capital Share based reserve Acquisition of Supreme Cannabis 9,013,400 $ 260,668 $ - Completion of acquisition milestones 1,295,285 29,276 (29,721 ) Other issuances 351,252 6,630 (405 ) Total 10,659,937 $ 296,574 $ (30,126 ) During the nine months ended December 31, 2020, the Company issued the following shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of shares Share capital Share based reserve Completion of acquisition milestones 1,149,086 $ 21,531 $ (13,009 ) Other issuances 412,417 14,135 (14,712 ) Total 1,561,503 $ 35,666 $ (27,721 )
Summary of Warrants	Number of whole warrants Average exercise price Warrant value Balance outstanding at March 31, 2021 1 127,073,136 $ 58.33 $ 2,568,438 Supreme Cannabis warrants 1,265,742 25.61 13,350 Expiry of warrants (145,831 ) 32.61 - Balance outstanding at December 31, 2021 1 128,193,047 $ 58.04 $ 2,581,788 1 Number of whole warrants Average exercise price Warrant value Balance outstanding at March 31, 2020 1 146,299,443 $ 52.44 $ 2,638,951 Exercise of warrants (18,876,901 ) 12.98 (70,266 ) Expiry of warrants (343,380 ) 41.49 - Balance outstanding at December 31, 2020 1 127,079,162 $ 58.30 $ 2,568,685 1

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Outstanding Stock Options	The following is a summary of the Options as at December 31, 2021: Options Outstanding Options Exercisable Weighted Average Weighted Average Remaining Remaining Outstanding at Contractual Life Exercisable at Contractual Life Range of Exercise Prices December 31, 2021 (years) December 31, 2021 (years) $0.06 - $24.62 3,789,682 4.31 1,263,512 2.14 $24.63 - $33.53 4,153,283 3.49 2,331,110 2.89 $33.54 - $36.80 3,229,461 2.51 3,229,461 2.51 $36.81 - $42.84 2,857,506 3.19 2,622,583 2.87 $42.85 - $171.54 3,707,258 3.13 2,921,964 3.06 17,737,190 3.36 12,368,630 2.75
Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model	The Company uses the Black-Scholes option pricing model to establish the fair value of Options granted during the three months ended December 31, 2021 and 2020, on their measurement date by applying the following assumptions: December 31, December 31, 2021 2020 Risk-free interest rate 1.21% 0.49% Expected life of options (years) 3 - 5 5 - 7 Expected volatility 75% 73% Expected forfeiture rate 18% 17% Expected dividend yield nil nil Black-Scholes value of each option $7.55 $23.53
Summary of Changes in RSUs	The following is a summary of the changes in the Company’s RSUs and PSUs during the nine months ended December 31, 2021: Number of RSUs and PSUs Balance outstanding at March 31, 2021 753,310 RSUs and PSUs granted 564,150 RSUs and PSUs released (197,316 ) RSUs and PSUs cancelled and forfeited (201,000 ) Balance outstanding at December 31, 2021 919,144
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Changes in Employee Stock Options	The following is a summary of the changes in the Options outstanding during the nine months ended December 31, 2021: Options issued Weighted average exercise price Balance outstanding at March 31, 2021 17,704,311 $ 36.79 Options granted 2,528,021 17.42 Replacement options issued as a result of the acquisition of Supreme Cannabis 140,159 80.53 Options exercised (421,476 ) 12.65 Options forfeited (2,213,825 ) 39.70 Balance outstanding at December 31, 2021 17,737,190 $ 34.17

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated other comprehensive income includes the following components: Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2021 $ (28,246 ) $ (5,994 ) $ (34,240 ) Other comprehensive income (loss) (18,767 ) 26,280 7,513 As at December 31, 2021 $ (47,013 ) $ 20,286 $ (26,727 ) Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2020 $ 126,723 $ 94,176 $ 220,899 Other comprehensive loss (110,932 ) (82,560 ) (193,492 ) As at December 31, 2020 $ 15,791 $ 11,616 $ 27,407

Noncontrolling Interests (Table

Noncontrolling Interests (Tables)	9 Months Ended
	Dec. 31, 2021
Noncontrolling Interest [Abstract]
Summary of Net Change in Noncontrolling Interests	The net change in the noncontrolling interests is as follows: Vert Mirabel BioSteel Other non- material interests Total As at March 31, 2021 $ - $ 1,658 $ 3,051 $ 4,709 Comprehensive loss (2,401 ) (10,699 ) (1,207 ) (14,307 ) Net loss attributable to redeemable noncontrolling interest 2,401 10,699 - 13,100 Share-based compensation - 684 - 684 As at December 31, 2021 $ - $ 2,342 $ 1,844 $ 4,186 Canopy Rivers Vert Mirabel BioSteel Other non- material interests Total As at March 31, 2020 $ 211,086 $ 7,132 $ 489 $ 3,051 $ 221,758 Comprehensive loss 4,060 (8,956 ) (4,287 ) - (9,183 ) Net loss attributable to redeemable noncontrolling interest - 5,593 4,287 - 9,880 Share-based compensation 2,471 - 918 - 3,389 Ownership changes 1,521 175 - - 1,696 Warrants 250 - - - 250 As at December 31, 2020 $ 219,388 $ 3,944 $ 1,407 $ 3,051 $ 227,790

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Dec. 31, 2021
Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis	The following table represents our financial assets and liabilities measured at estimated fair value on a recurring basis: Fair value measurement using Quoted prices Significant prices in other Significant active observable unobservable markets inputs inputs (Level 1) (Level 2) (Level 3) Total December 31, 2021 Assets: Short-term investments $ 807,884 $ - $ - $ 807,884 Restricted short-term investments 12,208 - - 12,208 Other financial assets 554 - 890,843 891,397 Liabilities: Convertible senior notes - 567,042 - 567,042 Liability arising from Acreage Arrangement - - 103,000 103,000 Warrant derivative liability - - 37,491 37,491 March 31, 2021 Assets: Short-term investments $ 1,144,563 $ - $ - $ 1,144,563 Restricted short-term investments 11,332 - - 11,332 Other financial assets 254 - 700,728 700,982 Liabilities: Convertible senior notes - 687,414 - 687,414 Liability arising from Acreage Arrangement - - 600,000 600,000 Warrant derivative liability - - 615,575 615,575
Level 2
Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments	The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 2 financial instruments: Financial asset / financial liability Valuation techniques Key inputs Convertible senior notes Convertible note pricing model Quoted prices in over-the-counter broker market
Level 3
Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments	The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value Acreage financial instrument Probability weighted expected return model Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value Number of common shares to be issued Increase or decrease in value and number of common shares will result in a decrease or increase in fair value Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Estimated premium on US legalization Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value Control premium Increase or decrease in estimated control premium will result in an increase or decrease in fair value Market access premium Increase or decrease in estimated market access premium will result in an increase or decrease in fair value TerrAscend Exchangeable Shares, TerrAscend Option Put option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Hempco Debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - October 2019, March 2020 Black-Sholes option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value TerrAscend warrants - December 2020 Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Arise Bioscience term loan, TerrAscend Canada term loan - Discounted cash flow Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value October 2019, March 2020 Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Wana financial instrument Monte Carlo simulation model Probability of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Volatility of Wana Increase or decrease in volatility will result in an increase or decrease in fair value Warrant derivative liability Monte Carlo simulation model Volatility of Canopy Growth share price Increase or decrease in volatility will result in an increase or decrease in fair value BioSteel redeemable NCI Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value Vert Mirabel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Summary of Disaggregation of Revenue	Revenue is dissaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Canadian recreational cannabis net revenue Business-to-business 1 $ 33,282 $ 43,129 $ 117,902 $ 120,286 Business-to-consumer 14,477 20,224 48,473 48,263 47,759 63,353 166,375 168,549 Canadian medical cannabis net revenue 2 12,919 13,947 39,504 41,745 60,678 77,300 205,879 210,294 International and other revenue C 3 9,675 17,642 33,005 46,567 Other 12,624 8,886 32,357 20,543 22,299 26,528 65,362 67,110 Global cannabis net revenue 82,977 103,828 271,241 277,404 Other consumer products Storz & Bickel 25,205 24,147 63,786 63,103 This Works 10,730 10,907 26,308 24,789 BioSteel 16,974 7,348 31,147 14,918 Other 5,086 6,298 16,073 17,996 Other consumer products revenue 57,995 48,700 137,314 120,806 Net revenue $ 140,972 $ 152,528 $ 408,555 $ 398,210

Other Income (Expense), Net (Ta

Other Income (Expense), Net (Tables)	9 Months Ended
	Dec. 31, 2021
Other Income And Expenses [Abstract]
Schedule of Other Income (Expense), Net	Other income (expense), net is dissaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Fair value changes on other financial assets $ (68,666 ) $ 281,359 $ (263,946 ) $ 385,219 Fair value changes on liability arising from Acreage Arrangement 59,000 (303,000 ) 497,000 (249,849 ) Fair value changes on convertible senior notes 606 (75,498 ) 81,342 (107,778 ) Fair value changes on warrant derivative liability 67,282 (193,998 ) 578,084 (93,455 ) Fair value changes on acquisition related contingent consideration and other 712 (3,066 ) 544 39,803 Interest income 1,575 7,310 6,977 19,078 Interest expense (26,408 ) (1,030 ) (77,618 ) (3,708 ) Foreign currency gain (loss) 990 710 2,902 (10,290 ) Loss on disposal of consolidated entity - - (1,653 ) - Other income (expense), net (809 ) (3,354 ) (12,863 ) (126 ) $ 34,282 $ (290,567 ) $ 810,769 $ (21,106 )

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	25. EARNINGS (LOSS) PER SHARE Basic and diluted earnings (loss) per share are calculated using the following numerators and denominators: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Basic (loss) earnings per share computation Net (loss) income attributable to common shareholders of Canopy Growth $ (108,925 ) $ (904,380 ) $ 272,435 $ (1,044,942 ) Weighted average number of common shares outstanding 393,818,282 372,908,767 390,423,083 369,418,037 Basic (loss) earnings per share $ (0.28 ) $ (2.43 ) $ 0.70 $ (2.83 ) Diluted (loss) earnings per share computation Net (loss) income used in the computation of basic (loss) earnings per share $ (108,925 ) $ (904,380 ) $ 272,435 $ (1,044,942 ) Numerator adjustments for diluted (loss) earnings per share: Adjustment to net loss attributable to noncontrolling interests and redeemable noncontrolling interest - - (13,100 ) - Removal of fair value changes on convertible senior notes - - (81,342 ) - Net (loss) income used in the computation of diluted (loss) earnings per share $ (108,925 ) $ (904,380 ) $ 177,993 $ (1,044,942 ) Weighted average number of common shares outstanding used in the computation of basic (loss) earnings per share 393,818,282 372,908,767 390,423,083 369,418,037 Denominator adjustments for diluted (loss) earnings per share: Dilutive impact of assumed exercise or conversion of: Convertible senior notes - - 12,454,620 - Redeemable noncontrolling interest - - 4,528,898 - Stock options - - 745,700 - Other securities - - 2,834,501 - Weighted average number of common shares for computation of diluted (loss) earnings per share 393,818,282 372,908,767 410,986,802 369,418,037 Diluted (loss) earnings per share 1 $ (0.28 ) $ (2.43 ) $ 0.43 $ (2.83 ) 1

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Summary of Consolidated Balance Sheet Impact at Acquisition of Company's Business Combinations	The following table summarizes the consolidated balance sheet impact at acquisition of the Company’s business combinations that occurred in the nine months ended December 31, 2021: Ace Supreme Valley Cannabis (i) (ii) Other Total Cash and cash equivalents $ 1,544 $ 41,306 $ 1,227 $ 44,077 Inventory 878 33,426 428 34,732 Other current assets 2,249 15,145 305 17,699 Property, plant and equipment 105 187,407 1,510 189,022 Intangible assets Brands 14,000 24,600 - 38,600 Distribution channel - 3,500 - 3,500 Operating licenses - 12,400 2,000 14,400 Goodwill 39,152 66,524 7,263 112,939 Accounts payable and other accrued expenses and liabilities (1,724 ) (13,056 ) - (14,780 ) Debt and other liabilities - (88,324 ) (1,037 ) (89,361 ) Deferred income tax liabilities (1,899 ) (3,260 ) (540 ) (5,699 ) Net assets acquired $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Consideration paid in shares - 260,668 4,052 264,720 Replacement options - 629 - 629 Replacement warrants - 13,350 - 13,350 Other consideration 2,469 4,937 - 7,406 Total consideration $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Less: Cash and cash equivalents acquired (1,544 ) (41,306 ) (1,227 ) (44,077 ) Net cash outflow (inflow) $ 50,292 $ (41,222 ) $ 5,877 $ 14,947

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The Company’s global cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Company’s other consumer products segment comprises the production, distribution and sale of consumer products, including (i) Storz & Bickel vaporizers; (ii) This Works beauty, skincare, wellness and sleep products; (iii) BioSteel sports nutrition beverages, mixes, protein, gum and mints; and (iv) other revenue sources. The Company’s CODM evaluates the performance of these two segments focusing on (i) segment net revenue, and (ii) segment gross margin and gross margin percentage as the measure of segment profit or loss. Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Segmented net revenue Global cannabis $ 82,977 $ 103,828 $ 271,241 $ 277,404 Other consumer products 57,995 48,700 137,314 120,806 $ 140,972 $ 152,528 $ 408,555 $ 398,210 Segmented gross margin: Global cannabis $ (11,209 ) $ 7,394 $ (80,432 ) $ 12,598 Other consumer products 21,299 17,191 46,620 44,562 10,090 24,585 (33,812 ) 57,160 Selling, general and administrative expenses 116,835 144,078 355,165 426,723 Share-based compensation 6,777 19,963 35,856 72,632 Expected credit losses on financial assets and relates charges - 13,735 - 108,480 Asset impairment and restructuring costs 36,439 400,422 128,198 459,579 Operating loss (149,961 ) (553,613 ) (553,031 ) (1,010,254 ) Loss from equity method investments - (671 ) (100 ) (40,851 ) Other income (expense), net 34,282 (290,567 ) 810,769 (21,106 ) Net (loss) income before incomes taxes $ (115,679 ) $ (844,851 ) $ 257,638 $ (1,072,211 )
Summary of Disaggregation of Net Revenue by Geographic Area	Disaggregation of net revenue by geographic area: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Canada $ 78,644 $ 91,060 $ 241,440 $ 243,084 Germany 23,143 31,262 71,619 87,649 United States 22,764 18,141 60,856 40,885 Other 16,421 12,065 34,640 26,592 $ 140,972 $ 152,528 $ 408,555 $ 398,210
Summary of Disaggregation of Long-lived Assets by Geographic Areas	Disaggregation of property, plant and equipment by geographic area: December 31, March 31, 2021 2021 Canada $ 876,331 $ 847,678 United States 140,299 143,747 Other 63,549 83,112 $ 1,080,179 $ 1,074,537

Asset Impairment and Restruct_2

Asset Impairment and Restructuring Costs - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Restructuring And Related Activities [Abstract]
Asset impairment and restructuring costs	$ 36,439	$ 400,422	$ 128,198	$ 459,579

Cash and Cash Equivalents - Com

Cash and Cash Equivalents - Components of Cash and Cash Equivalents (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Cash And Cash Equivalents [Abstract]
Cash	$ 421,675	$ 436,588
Cash equivalents	193,471	718,065
Cash And Cash Equivalents At Carrying Value	$ 615,146	$ 1,154,653

Short-term Investments - Compon

Short-term Investments - Components of Short-term Investments (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Marketable Securities [Line Items]
Short-term investments	$ 807,884	$ 1,144,563
Term Deposits
Marketable Securities [Line Items]
Short-term investments	354,745	463,824
Asset-backed Securities
Marketable Securities [Line Items]
Short-term investments	63,197	16,342
Government securities
Marketable Securities [Line Items]
Short-term investments	21,026	136,620
Commercial paper and other
Marketable Securities [Line Items]
Short-term investments	$ 368,916	$ 527,777

Short-term Investments - Additi

Short-term Investments - Additional Information (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Short Term Investments [Abstract]
Amortized cost of short-term investments	$ 809,722	$ 1,145,364

Amounts Receivable, Net - Compo

Amounts Receivable, Net - Components of Amounts Receivable, Net (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Receivables [Abstract]
Accounts receivable, net	$ 82,554	$ 67,106
Indirect taxes receivable	6,553	8,281
Interest receivable	5,372	5,140
Other receivables	6,422	11,908
Amounts receivable, net	$ 100,901	$ 92,435

Amounts Receivable, Net - Addit

Amounts Receivable, Net - Additional Information (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Receivables [Abstract]
Allowance for doubtful accounts	$ 2,037	$ 1,411

Inventory - Components of Inven

Inventory - Components of Inventory (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Inventory Disclosure [Abstract]
Raw materials, packaging supplies and consumables	$ 55,741	$ 55,554
Work in progress	166,425	223,652
Finished goods	143,584	88,773
Inventory	$ 365,750	$ 367,979

Inventory - Additional Informat

Inventory - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventory write-downs	$ 11,811	$ 23,836	$ 104,662	$ 48,167

Prepaid Expenses and Other As_3

Prepaid Expenses and Other Assets - Components of Prepaid and Other Assets (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Prepaid Expense And Other Assets Current [Abstract]
Prepaid expenses	$ 31,292	$ 28,349
Deposits	19,200	18,316
Prepaid inventory	1,244	1,496
Other assets	34,531	19,071
Prepaid and other assets	$ 86,267	$ 67,232

Other Financial Assets - Summar

Other Financial Assets - Summary of Changes in Other Financial Assets (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2021CAD ($)
Schedule Of Investments [Line Items]
Beginning balance	$ 708,167
Other Financial Assets Additions	448,684
Fair value changes	(263,946)
Foreign currency translation adjustments	9,636
Interest Income (Expense), Net	(3,867)
Exercise of options / disposal of shares	(177)
Ending balance	898,497
TerrAscend Exchangeable Shares | Exchangeable Shares
Schedule Of Investments [Line Items]
Beginning balance	385,000
Fair value changes	(166,000)
Ending balance	219,000
TerrAscend Canada - October 2019 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	17,250
Fair value changes	(10,770)
Ending balance	6,480
TerrAscend Canada - October 2019 | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	10,240
Fair value changes	750
Ending balance	10,990
TerrAscend - March 2020 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	152,910
Fair value changes	(73,830)
Ending balance	79,080
Arise Bioscience | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	56,330
Fair value changes	550
Ending balance	56,880
TerrAscend - December 2020 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	13,240
Fair value changes	(6,920)
Ending balance	6,320
Acreage Hempco1 | Debenture
Schedule Of Investments [Line Items]
Beginning balance	27,448	[1]
Fair value changes	4,023	[1]
Foreign currency translation adjustments	197	[1]
Interest Income (Expense), Net	(3,867)	[1]
Ending balance	27,801	[1]
Arise Bioscience | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	13,077
Fair value changes	921
Foreign currency translation adjustments	105
Ending balance	14,103
TerrAscend | Equity Option
Schedule Of Investments [Line Items]
Beginning balance	10,600
Fair value changes	(4,600)
Ending balance	6,000
Wana | Equity Option
Schedule Of Investments [Line Items]
Other Financial Assets Additions	442,227
Foreign currency translation adjustments	9,472
Ending balance	451,699
Other At Fair Value Through Net Income Loss | Various
Schedule Of Investments [Line Items]
Beginning balance	14,887
Other Financial Assets Additions	6,457
Fair value changes	(8,070)
Foreign currency translation adjustments	(138)
Exercise of options / disposal of shares	(92)
Ending balance	13,044
Other - Classified as Held for Investment | Loan Receivable
Schedule Of Investments [Line Items]
Beginning balance	7,185
Exercise of options / disposal of shares	(85)
Ending balance	$ 7,100
[1]	See Note 27 for information regarding Acreage Hempco

Other Financial Assets -Additio

Other Financial Assets -Additional Information (Details) - Oct. 14, 2021 $ in Thousands, $ in Thousands	CAD ($)Number	USD ($)Number
Schedule Of Investments [Line Items]
Estimated Deferred Payments	$ 74,160
Deferred Payment1
Schedule Of Investments [Line Items]
Percentage of Fair Value at the time of Option Exercised	25.00%
Estimate Fair Value Anniversary Year	2 years 6 months
Deferred Payment2
Schedule Of Investments [Line Items]
Percentage of Fair Value at the time of Option Exercised	25.00%
Estimate Fair Value Anniversary Year	5 years
Wana
Schedule Of Investments [Line Items]
Outstanding Membership Interests	100.00%	100.00%
Number of option agreements | Number	3	3
Outstanding Membership Interests	100.00%	100.00%
Proceeds from Warrant Exercises	$ 368,067
Percentage of Fair Value at the time of Option Exercised	15.00%
Debt Instrument, Fair Value Disclosure	$ 442,227
Estimated Deferred Payments	$ 74,160
Percentage Of Outstanding Membership Interest Acquired	100.00%
Wana | Deferred Payment1
Schedule Of Investments [Line Items]
Upfront payment anniversary years	2 years 6 months
Wana | Deferred Payment2
Schedule Of Investments [Line Items]
Upfront payment anniversary years	5 years
Wana | U S D
Schedule Of Investments [Line Items]
Proceeds from Warrant Exercises		$ 297,500

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Components of Property, Plant and Equipment (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,315,593	$ 1,297,127
Less: Accumulated depreciation	(235,414)	(222,590)
Property, plant and equipment, net	1,080,179	1,074,537
Buildings and Greenhouses
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	820,863	651,166
Buildings and Greenhouses | Right-of-Use-Assets
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	99,355	100,517
Production and Warehouse Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	204,790	216,925
Production and Warehouse Equipment | Right-of-Use-Assets
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	182	530
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	86,307	106,837
Land
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	23,410	34,747
Office and Lab Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	32,093	30,546
Computer Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	23,097	26,431
Assets in Process
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 25,496	$ 129,428

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment			$ 56,467	$ 54,625
Cost of Goods Sold
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment	$ 13,813	$ 10,955	38,663	40,190
Selling, General and Administrative Expenses
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment	$ 5,546	$ 7,297	$ 17,804	$ 14,435

Intangible Assets - Summary of

Intangible Assets - Summary of Components of Intangible Assets (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	$ 354,934	$ 337,456
Net Carrying Amount	223,973	232,826
Total intangible assets	338,753	308,167
Intellectual Property
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	209,650	212,100
Net Carrying Amount	157,206	168,655
Distribution Channel
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	76,963	73,756
Net Carrying Amount	29,568	35,176
Software and Domain Names
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	30,517	27,836
Net Carrying Amount	13,855	18,149
Brands
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	21,675	21,812
Net Carrying Amount	8,143	8,894
Operating Licenses
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	12,400	0
Net Carrying Amount	11,472	0
Indefinite lived intangible assets	10,000	8,000
Amortizable Intangibles in Process
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	3,729	1,952
Net Carrying Amount	3,729	1,952
Acquired Brands
Intangible Assets Net Excluding Goodwill [Line Items]
Indefinite lived intangible assets	$ 104,780	$ 67,341

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets			$ 27,462	$ 43,565
Cost of Goods Sold
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 19	$ 99	62	62
Selling, General and Administrative Expenses
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 10,639	$ 14,034	$ 27,400	$ 43,503

Goodwill - Changes in Carrying

Goodwill - Changes in Carrying Amount of Goodwill (Details) - CAD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Goodwill [Line Items]
Beginning Balance	$ 1,889,354	$ 1,954,471
Purchase accounting allocations	112,939
Foreign currency translation adjustments	(8,798)	(65,117)
Ending Balance	1,988,250	$ 1,889,354
Consolidated Entities
Goodwill [Line Items]
Disposal of consolidated entities	$ (5,245)

Other Accrued Expenses and Li_3

Other Accrued Expenses and Liabilities - Components of Other Accrued Expenses and Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Accounts Payable And Accrued Liabilities Current [Abstract]
Employee compensation	$ 22,559	$ 47,237
Taxes and government fees	7,684	13,550
Professional fees	7,319	11,544
Other	38,445	28,482
Other accrued expenses and liabilities	$ 76,007	$ 100,813

Debt - Summary of Components of

Debt - Summary of Components of Debt (Details) $ in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2021CAD ($)	Mar. 31, 2021CAD ($)	Mar. 18, 2021USD ($)
Debt Instrument [Line Items]
Principal amount			$ 750,000
Other revolving debt facility, loan, and financings	$ 3,155	$ 3,872
Long Term Debt	1,510,367	1,582,963
Current portion of long-term debt	15,702	9,827
Long-term debt	1,494,665	1,573,136
Debt	1,510,367	1,582,963
Less: current portion	(15,702)	(9,827)
Long-term portion	$ 1,494,665	1,573,136
4.25% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Convertible senior notes at 4.25%, Maturity Date	Jul. 15, 2023
Principal amount	$ 600,000	600,000
Accrued interest	12,042	5,664
Non-credit risk fair value adjustment	9,240	109,710
Credit risk fair value adjustment	(54,240)	(27,960)
Senior Notes	$ 567,042	687,414
Convertible Debentures
Debt Instrument [Line Items]
Convertible debentures	Sep. 10, 2025
Convertible debentures	$ 31,689	0
Accretion Debentures
Debt Instrument [Line Items]
Convertible debentures	Sep. 10, 2025
Accretion debentures	$ 7,478	0
Revolving Credit Facility
Debt Instrument [Line Items]
Convertible debentures	Mar. 18, 2026
Credit facility	$ 901,003	$ 891,677

Debt - Summary of Components _2

Debt - Summary of Components of Debt (Parenthetical) (Details)	Dec. 31, 2021
4.25% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Annual interest rate	4.25%

Debt - Additional Information (

Debt - Additional Information (Details)	Mar. 18, 2021CAD ($)	Mar. 18, 2021USD ($)	Aug. 13, 2019CAD ($)	Jun. 20, 2018CAD ($)Trading_Day$ / shares	Sep. 09, 2020CAD ($)$ / shares	Oct. 19, 2018CAD ($)	Dec. 31, 2021CAD ($)	Dec. 31, 2020CAD ($)	Dec. 31, 2021CAD ($)	Dec. 31, 2020CAD ($)
Debt Instrument [Line Items]
Principal amount		$ 750,000,000
Proceeds from the Credit Facility	$ 893,160,000
Accretion Rate					11.06%
Conversion Of Outstanding Debentures Description					In addition, the Company may force conversion of the Supreme Debentures outstanding with 30 days’ notice if the daily volume weighted average trading price of the Company’s common shares is greater than $38.59 for any 10 consecutive trading days. The Company, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby the Company agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures.
Supreme Cannabis [Member]
Debt Instrument [Line Items]
Interest at a rate						6.00%
Annual interest rate						6.00%
Proceeds from the Credit Facility						$ 100,000,000
Maturity date					Sep. 10, 2025
Conversion price | $ / shares					$ 0.285
Cancellation of Debt					$ 63,500,000
Convertible senior notes at 4.25%, Maturity Date					Sep. 10, 2025
Monthly Interest Rate					1.00%
Farm Credit Canada | Tweed Inc. | Revolving Credit Facility
Debt Instrument [Line Items]
Interest at a rate							3.45%		3.45%
Annual interest rate							3.45%		3.45%
Line of credit facility, maximum borrowing capacity			$ 40,000,000
Extinguishment of debt, amount			$ 4,912,000
Debt instrument, description of variable rate basis									prime rate plus 1.0%
Debt Instrument, Basis Spread on Variable Rate									1.00%
Minimum
Debt Instrument [Line Items]
Liquidity requirement		200,000,000
Minimum | Supreme Cannabis [Member]
Debt Instrument [Line Items]
Proceeds from the Credit Facility					$ 13,500,000
Maximum [Member] | Supreme Cannabis [Member]
Debt Instrument [Line Items]
Interest at a rate					8.00%
Annual interest rate					8.00%
Proceeds from the Credit Facility					$ 36,500,000
Credit Facility
Debt Instrument [Line Items]
Senior credit facility		$ 500,000
4.25% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest at a rate		8.50%
Annual interest rate		8.50%
L I B O R Floor
Debt Instrument [Line Items]
Interest at a rate		1.00%
Annual interest rate		1.00%
4.25% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal amount				$ 600,000,000
Interest at a rate				4.25%
Annual interest rate				4.25%
Frequency of periodic payment team				semi-annually on January 15th and July 15th of each year commencing from January 15, 2019
Maturity date				Jul. 15, 2023
Convertible senior notes conversion time start from				Jan. 15, 2023
Conversion rate for every dollar one of principal amount of notes | $ / shares				$ 20.7577
Convertible, If-converted value in excess of principal				$ 1,000
Conversion price | $ / shares				$ 48.18
Debt Conversion, Description				(i) the market price of the Company common shares for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the 5 business day period after any consecutive 5 trading day period (the “Measurement Period”) in which the trading price per $1 principal amount of the Notes for each trading day in the Measurement Period was less than 98% of the product of the last reported sales price of the Company’s common shares and the conversion rate on each such trading day, (iii) the Notes are called for redemption or (iv) upon occurrence of certain corporate events (a “Fundamental Change”). A Fundamental Change occurred upon completion of the investment by Constellation Brands, Inc. (“CBI”) in the Company in November 2018, and no holders of Notes surrendered any portion of their Notes in connection therewith
Conversion price percentage				130.00%					130.00%
Convertible measurement period threshold trading days				5 days
Convertible measurement period threshold consecutive trading days				5 days
Convertible conversion price | $ / shares				$ 1
Maximum discount to last reported sales price				98.00%
Debt instrument, redemption, description									Prior to July 20, 2021, the Company could not redeem the Notes except in the event of certain changes in Canadian tax law.
Debt instrument, redemption period, start date									Jul. 20, 2021
Debt instrument, redemption threshold trading days									20 days
Debt instrument, redemption threshold consecutive trading days									30 days
Number of trading days to provide notice of redemption									5 days
Debt instrument, redemption price, percentage									100.00%
Debt instrument, change in fair value of notes							$ 16,806,000	$ 105,588,000	$ 120,372,000	$ 177,588,000
Debt instrument, change in fair value of notes from contractual interest							$ 6,444,000	$ 6,588,000	$ 19,128,000	$ 19,338,000
Convertible senior notes at 4.25%, Maturity Date				Jul. 15, 2023
4.25% Convertible Senior Notes [Member] | Minimum
Debt Instrument [Line Items]
Threshold consecutive trading days | Trading_Day				20
4.25% Convertible Senior Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Threshold consecutive trading days | Trading_Day				30

Other Liabilities - Components

Other Liabilities - Components of Other Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Other Liabilities Current [Abstract]
Lease liabilities	$ 38,684	$ 42,061
Acquisition consideration and other investment related liabilities	4,078	16,577
Refund liability	6,046	6,441
Settlement liabilities and other	30,892	41,349
Other Liabilities Current	79,700	106,428
Long-term
Lease liabilities, long-term	104,300	94,164
Acquisition consideration and other investment related liabilities	83,681	7,808
Settlement liabilities and other	7,637	5,268
Other liabilities, long-term	195,618	107,240
Total
Lease liabilities	142,984	136,225
Acquisition consideration and other investment related liabilities	87,759	24,385
Refund liability	6,046	6,441
Settlement liabilities and other	38,529	46,617
Other liabilities	$ 275,318	$ 213,668

Other Liabilities - Additional

Other Liabilities - Additional Information (Details) $ in Thousands	Oct. 14, 2021CAD ($)
Other Liabilities Disclosure [Abstract]
Estimated Deferred Payments	$ 74,160

Redeemable Noncontrolling Int_3

Redeemable Noncontrolling Interest - Summary of Net Change in Redeemable Noncontrolling Interests (Details) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	$ 135,300	$ 69,750
Net loss attributable to redeemable noncontrolling interest	(13,100)	(9,880)
Adjustments to redemption amount	(48,391)	51,230
Ending balance	68,700	111,100
Redeemable Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Redemption of redeemable noncontrolling interest	(5,109)
Vert Mirabel
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	11,500	20,250
Net loss attributable to redeemable noncontrolling interest	(2,401)	(5,593)
Adjustments to redemption amount	2,401	5,543
Ending balance	11,500	20,200
Bio Steel
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	123,800	49,500
Net loss attributable to redeemable noncontrolling interest	(10,699)	(4,287)
Adjustments to redemption amount	(50,792)	45,687
Ending balance	57,200	$ 90,900
Bio Steel | Redeemable Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Redemption of redeemable noncontrolling interest	$ (5,109)

Share Capital - Additional Info

Share Capital - Additional Information (Details)	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Number of equity financings	0	0

Share Capital - Summary of Issu

Share Capital - Summary of Issuances of Stock Other (Details) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones, Number of shares	1,295,285	1,149,086
Share Capital
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones	$ 29,276	$ 21,531
Share-based Reserve
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones	$ (29,721)	$ (13,009)
Acquisition Of Supreme Cannabis [Member]
Equity Class Of Treasury Stock [Line Items]
Number of shares	9,013,400
Share capital	$ 260,668
Other Issuances [Member]
Equity Class Of Treasury Stock [Line Items]
Number of shares	351,252	412,417
Share capital	$ 6,630	$ 14,135
Share based reserve	$ (405)	$ (14,712)
Total [Member]
Equity Class Of Treasury Stock [Line Items]
Number of shares	10,659,937	1,561,503
Share capital	$ 296,574	$ 35,666
Share based reserve	$ (30,126)	$ (27,721)

Share Capital - Summary of Warr

Share Capital - Summary of Warrants (Details) - CAD ($)	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Warrants And Rights Note Disclosure [Abstract]
Number of whole warrants, Beginning balance	127,073,136	146,299,443
Number of whole warrants,Supreme Cannabis Warrants	1,265,742
Number of whole warrants, Expiry of warrants	(145,831)	(343,380)
Number of whole warrants, Ending balance	128,193,047	127,079,162
Average exercise price, Beginning balance	$ 58.33	$ 52.44
Average exercise price,Supreme Cannabis warrants	25.61
Average exercise price, Expiry of warrants	$ 32.61	41.49
Average exercise price, Ending balance	$ 58.04	$ 58.30
Warrant value, Beginning balance	$ 2,568,438,000	$ 2,638,951,000
Warrant Value, Supreme Cannabis warrants	13,350,000
Warrant value, Expiry of warrants
Warrant value, Ending balance	$ 2,581,788,000	$ 2,568,685,000
Number of whole warrants, Exercise of warrants		(18,876,901)
Number of whole warrants, Expiry of warrants	145,831	343,380
Average exercise price, Exercise of warrants		$ 12.98
Warrant Value, Exercise of warrants		$ (70,266,000)

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - CAD ($) $ / shares in Units, $ in Thousands	May 27, 2021	Sep. 21, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Jun. 22, 2021	Mar. 31, 2021	Mar. 31, 2020	Oct. 01, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options extended period		10 years
Options maximum period		6 years
Weighted average exercise price of options outstanding			$ 34.17		$ 34.17			$ 36.79
Weighted average exercise price of options exercisable			$ 38.05		$ 38.05			36.97
Proceeds from exercise of stock options					$ 5,455	$ 37,999
Number of common shares released on completion of acquisition milestones			419,884		1,295,285	1,149,086
Number of shares to be issued on completion of acquisition and asset purchase milestones					256,057
Stock options outstanding			17,737,190		17,737,190
Share-based compensation			$ 6,777	$ 19,963	$ 35,856	$ 72,632
Canopy Rivers Corporation
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense				381		2,471
Supreme Cannabis [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense					$ 823
Percentage of outstanding shares purchased							100.00%
Bio Steel Sports Nutrition Inc
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of outstanding shares purchased										72.00%
Stock options outstanding			1,545,300		1,545,300				1,581,000
Vesting period					5 years
Share-based compensation			$ 160	256	$ 684	918
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense			3,696	16,663	$ 22,038	$ 54,516
Stock Option Subject To Performance Conditions
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense, options subject to performance conditions					1,559,413	2,112,745
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense			$ 1,950	$ 2,685	$ 7,935	$ 8,870
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common shares reserved for Awards			39,415,800		39,415,800
Options expiration period		10 years
Weighted average exercise price of options outstanding			$ 34.17		$ 34.17			$ 36.79
Options exercised					421,476	3,176,977
Exercise price					$ 12.65
Proceeds from exercise of stock options					$ 5,455	$ 37,999
Stock options outstanding			17,737,190		17,737,190			17,704,311
Omnibus Incentive Plan | Share-based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of options exercisable on each anniversaries from date of grant		33.33%
Omnibus Incentive Plan | Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of options exercisable on each anniversaries from date of grant		33.33%
Omnibus Incentive Plan | Share-based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of options exercisable on each anniversaries from date of grant		33.33%
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate number of common shares authorized			600,000		600,000
Equity shares issued to shareholders			61,103		61,103
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares issuable from treasury pursuant to awards	15.00%
Maximum [Member] | Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price					$ 36.34	$ 36.34
Maximum [Member] | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity shares issued to shareholders					300,000
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares issuable from treasury pursuant to awards	10.00%
Minimum | Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price					$ 0.06	$ 0.06

Share-Based Compensation - Summ

Share-Based Compensation - Summary of the Changes in Options Outstanding Under the Omnibus Plan (Details) - shares	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, ending balance	17,737,190
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, beginning balance	17,704,311
Options granted	2,528,021
Replacement options issued as a result of the acquisition of Supreme Cannabis	140,159
Options exercised	(421,476)	(3,176,977)
Options forfeited	(2,213,825)
Options outstanding, ending balance	17,737,190

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of the Changes in Omnibus Plan Employee Options (Details)	9 Months Ended
	Dec. 31, 2021$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average exercise price outstanding, beginning balance	$ 36.79
Weighted average exercise price outstanding, ending balance	34.17
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average exercise price outstanding, beginning balance	36.79
Weighted average exercise price, Options granted	17.42
Replacement options issued as a result of the acquisition of Supreme Cannabis	80.53
Weighted average exercise price, Options exercised	12.65
Weighted average exercise price, Options forfeited	39.70
Weighted average exercise price outstanding, ending balance	$ 34.17

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Outstanding Stock Options (Details)	9 Months Ended
	Dec. 31, 2021$ / sharesshares
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Options Outstanding	17,737,190
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 4 months 9 days
Options Exercisable	12,368,630
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 9 months
Range One
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 0.06
Range of Exercise Prices, Upper Range | $ / shares	$ 24.62
Options Outstanding	3,789,682
Options Outstanding, Weighted Average Remaining Contractual Life	4 years 3 months 21 days
Options Exercisable	1,263,512
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 1 month 20 days
Range Two
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 24.63
Range of Exercise Prices, Upper Range | $ / shares	$ 33.53
Options Outstanding	4,153,283
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 5 months 26 days
Options Exercisable	2,331,110
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 10 months 20 days
Range Three
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 33.54
Range of Exercise Prices, Upper Range | $ / shares	$ 36.80
Options Outstanding	3,229,461
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 6 months 3 days
Options Exercisable	3,229,461
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 6 months 3 days
Range Four
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 36.81
Range of Exercise Prices, Upper Range | $ / shares	$ 42.84
Options Outstanding	2,857,506
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 2 months 8 days
Options Exercisable	2,622,583
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 10 months 13 days
Range Five
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 42.85
Range of Exercise Prices, Upper Range | $ / shares	$ 171.54
Options Outstanding	3,707,258
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 1 month 17 days
Options Exercisable	2,921,964
Options Exercisable, Weighted Average Remaining Contractual Life	3 years 21 days

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model (Details) - $ / shares	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	1.21%	0.49%
Expected volatility	75.00%	73.00%
Expected forfeiture rate	18.00%	17.00%
Expected dividend yield		0.00%
Black-Scholes value of each option	$ 7.55	$ 23.53
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)	3 years	5 years
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)	5 years	7 years

Share-Based Compensation - Su_5

Share-Based Compensation - Summary of the Changes in RSUs (Details) - RSUs	9 Months Ended
	Dec. 31, 2021shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	753,310
RSUs and PSUs granted	564,150
RSUs and PSUs released	(197,316)
RSUs and PSUs cancelled and forfeited	(201,000)
Ending balance	919,144

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Details) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ 3,486,520	$ 5,108,120
Other comprehensive income (loss)	7,513	(193,492)
Ending balance	4,142,944	4,184,422
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(28,246)	126,723
Other comprehensive income (loss)	(18,767)	(110,932)
Ending balance	(47,013)	15,791
Changes of Own Credit Risk of Financial Liabilities
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(5,994)	94,176
Other comprehensive income (loss)	26,280	(82,560)
Ending balance	20,286	11,616
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(34,240)	220,899
Ending balance	$ (26,727)	$ 27,407

Noncontrolling Interests - Summ

Noncontrolling Interests - Summary of Net Change in Noncontrolling Interests (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Minority Interest [Line Items]
Beginning balance			$ 3,486,520	$ 5,108,120
Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest	$ (6,571)	$ 75,129	(14,307)	(9,183)
Net loss attributable to redeemable noncontrolling interest			13,100	9,880
Share-based compensation	6,777	19,963	35,856	72,632
Ending balance	4,142,944	4,184,422	4,142,944	4,184,422
Comprehensive income (loss)	(6,571)	75,129	(14,307)	(9,183)
Noncontrolling Interests
Minority Interest [Line Items]
Beginning balance			4,709	221,758
Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest			(14,307)	(9,183)
Net loss attributable to redeemable noncontrolling interest			13,100	9,880
Share-based compensation			684	3,389
Ending balance	4,186	227,790	4,186	227,790
Comprehensive income (loss)			(14,307)	(9,183)
Ownership changes				1,696
Warrants				250
Vert Mirabel
Minority Interest [Line Items]
Beginning balance				7,132
Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest			(2,401)	(8,956)
Net loss attributable to redeemable noncontrolling interest			2,401	5,593
Ending balance		3,944		3,944
Comprehensive income (loss)			(2,401)	(8,956)
Ownership changes				175
Bio Steel
Minority Interest [Line Items]
Beginning balance			1,658	489
Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest			(10,699)	(4,287)
Net loss attributable to redeemable noncontrolling interest			10,699	4,287
Share-based compensation			684	918
Ending balance	2,342	1,407	2,342	1,407
Comprehensive income (loss)			(10,699)	(4,287)
Other Non Material Interests
Minority Interest [Line Items]
Beginning balance			3,051	3,051
Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest			(1,207)
Ending balance	$ 1,844	3,051	1,844	3,051
Comprehensive income (loss)			$ (1,207)
Canopy Rivers [Member]
Minority Interest [Line Items]
Beginning balance				211,086
Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest				4,060
Share-based compensation				2,471
Ending balance		$ 219,388		219,388
Comprehensive income (loss)				4,060
Ownership changes				1,521
Warrants				$ 250

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis (Details) - Fair Value Measurements Recurring - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Assets:
Short-term investments	$ 807,884	$ 1,144,563
Restricted short-term investments	12,208	11,332
Other financial assets	891,397	700,982
Liabilities:
Convertible senior notes	567,042	687,414
Acreage
Liabilities:
Derivative liability	103,000	600,000
Warrant
Liabilities:
Derivative liability	37,491	615,575
Level 1
Assets:
Short-term investments	807,884	1,144,563
Restricted short-term investments	12,208	11,332
Other financial assets	554	254
Level 2
Liabilities:
Convertible senior notes	567,042	687,414
Level 3
Assets:
Other financial assets	890,843	700,728
Level 3 | Acreage
Liabilities:
Derivative liability	103,000	600,000
Level 3 | Warrant
Liabilities:
Derivative liability	$ 37,491	$ 615,575

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 Financial Instruments (Details) - Level 2 - Convertible Senior Notes	9 Months Ended
	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Convertible note pricing model
Key inputs	Quoted prices in over-the-counter broker market

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 3 Financial Instruments (Details) - Level 3	9 Months Ended
	Dec. 31, 2021
Acreage Financial Instrument Probability of Each Scenario
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Probability weighted expected return model
Significant unobservable inputs	Probability of each scenario
Relationship of unobservable inputs to fair value	Change in probability of occurrence in each scenario will result in a change in fair value
Acreage Financial Instrument Value and Number of Canopy Shares Issued
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Number of common shares to be issued
Relationship of unobservable inputs to fair value	Increase or decrease in value and number of common shares will result in a decrease or increase in fair value
Acreage Financial Instrument Intrinsic Value of Acreage
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Acreage Financial Instrument Probability and Timing of US Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Estimated premium on US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value
Acreage Financial Instrument Estimated Premium on US Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Control premium
Relationship of unobservable inputs to fair value	Increase or decrease in estimated control premium will result in an increase or decrease in fair value
Acreage Financial Instrument Control Premium
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Market access premium
Relationship of unobservable inputs to fair value	Increase or decrease in estimated market access premium will result in an increase or decrease in fair value
TerrAscend Exchangeable Shares, TerrAscend Option
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Put option pricing model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Hempco Debenture
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
TerrAscend Warrants - October 2019, March 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Black-Sholes option pricing model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
TerrAscend warrants - December 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Arise Bioscience term loan
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
TerrAscend Canada Term Loan - October 2019 March 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Wana Financial Instrument Probability and Timing of US Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Probability of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Wana Financial Instrument Volatility of Wana
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Volatility of Wana
Relationship of unobservable inputs to fair value	Increase or decrease in volatility will result in an increase or decrease in fair value
Warrant Derivative Liability Volatility of Canopy Growth Share Price
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Volatility of Canopy Growth share price
Relationship of unobservable inputs to fair value	Increase or decrease in volatility will result in an increase or decrease in fair value
BioSteel Redeemable Noncontrolling Interest Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
BioSteel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Future wholesale price and production levels
Relationship of unobservable inputs to fair value	Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value
Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Future wholesale price and production levels
Relationship of unobservable inputs to fair value	Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value

Fair Value of Financial Instr_6

Fair Value of Financial Instruments - Additional Information (Details) - CAD ($)	Dec. 31, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair value, transfers of amounts between levels	$ 0	$ 0

Revenue - Summary of Disaggrega

Revenue - Summary of Disaggregation of Revenue (Details) - CAD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Net revenue		$ 140,972	$ 152,528	$ 408,555	$ 398,210
Canadian Recreational Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Net revenue		47,759	63,353	166,375	168,549
Canadian Medical Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Net revenue	[1]	12,919	13,947	39,504	41,745
Canadian Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Net revenue		60,678	77,300	205,879	210,294
International and Other Revenue
Disaggregation Of Revenue [Line Items]
Net revenue		22,299	26,528	65,362	67,110
Global Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Net revenue		82,977	103,828	271,241	277,404
Consumer Products and Other
Disaggregation Of Revenue [Line Items]
Net revenue		57,995	48,700	137,314	120,806
C3 | International and Other Revenue
Disaggregation Of Revenue [Line Items]
Net revenue		9,675	17,642	33,005	46,567
Business to Business | Canadian Recreational Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Net revenue	[2]	33,282	43,129	117,902	120,286
Business to Consumer | Canadian Recreational Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Net revenue		14,477	20,224	48,473	48,263
Other | International and Other Revenue
Disaggregation Of Revenue [Line Items]
Net revenue		12,624	8,886	32,357	20,543
Other | Consumer Products and Other
Disaggregation Of Revenue [Line Items]
Net revenue		5,086	6,298	16,073	17,996
Storz & Bickel | Consumer Products and Other
Disaggregation Of Revenue [Line Items]
Net revenue		25,205	24,147	63,786	63,103
This Work | Consumer Products and Other
Disaggregation Of Revenue [Line Items]
Net revenue		10,730	10,907	26,308	24,789
Bio Steel | Consumer Products and Other
Disaggregation Of Revenue [Line Items]
Net revenue		$ 16,974	$ 7,348	$ 31,147	$ 14,918
[1]	Canadian medical cannabis net revenue for the three and nine months ended December 31, 2021 reflects excise taxes of $1,298 and $4,039, respectively (three and nine months ended December 31, 2020 – $1,402 and $4,190, respectively).
[2]	Canadian recreational business-to-business net revenue during the three and nine months ended December 31, 2021 reflects excise taxes of $12,754 and $43,501, respectively (three and nine months ended December 31, 2020

Revenue - Summary of Disaggre_2

Revenue - Summary of Disaggregation of Revenue (Parenthetical) (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Excise taxes	$ 14,052	$ 17,379	$ 47,540	$ 41,613
C A | Recreational Cannabis Revenue
Disaggregation Of Revenue [Line Items]
Excise taxes	12,754	15,977	43,501	37,423
C A | Medical Cannabis Revenue
Disaggregation Of Revenue [Line Items]
Excise taxes	$ 1,298	$ 1,402	$ 4,039	$ 4,190

Revenue - Additional Informatio

Revenue - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Allowance for estimated returns and price adjustments	$ 1,000	$ 3,750	$ 4,000	$ 10,900
Liability for estimated returns and price adjustments	$ 6,046		$ 6,046		$ 6,441

Other Income (Expense), Net - S

Other Income (Expense), Net - Schedule of Other Income (Expense), Net (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Other Income And Expenses [Abstract]
Fair value changes on other financial assets	$ (68,666)	$ 281,359	$ (263,946)	$ 385,219
Fair value changes on liability arising from Acreage Arrangement	59,000	(303,000)	497,000	(249,849)
Fair value changes on convertible senior notes	606	(75,498)	81,342	(107,778)
Fair value changes on warrant derivative liability	67,282	(193,998)	578,084	(93,455)
Fair value changes on acquisition related contingent consideration and other	712	(3,066)	544	39,803
Interest income	1,575	7,310	6,977	19,078
Interest expense	(26,408)	(1,030)	(77,618)	(3,708)
Foreign currency gain (loss)	990	710	2,902	(10,290)
Loss on disposal of consolidated entity			(1,653)
Other income (expense), net	(809)	(3,354)	(12,863)	(126)
Other income (expense), net	$ 34,282	$ (290,567)	$ 810,769	$ (21,106)

Earnings (Loss) Per Share - Com

Earnings (Loss) Per Share - Computation of Basic and Diluted Earnings (Loss) Per Share (Details) - CAD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Basic (loss) earnings per share computation
Net (loss) income attributable to common shareholders of Canopy Growth		$ (108,925)	$ (904,380)	$ 272,435	$ (1,044,942)
Basic weighted average common shares outstanding		393,818,282	372,908,767	390,423,083	369,418,037
Basic (loss) earnings per share		$ (0.28)	$ (2.43)	$ 0.70	$ (2.83)
Diluted (loss) earnings per share computation
Net (loss) income used in the computation of basic (loss) earnings per share		$ (108,925)	$ (904,380)	$ 272,435	$ (1,044,942)
Adjustment to net loss attributable to noncontrolling interests and redeemable noncontrolling interest				(13,100)
Removal of fair value changes on convertible senior notes				(81,342)
Net (loss) income used in the computation of diluted (loss) earnings per share		$ (108,925)	$ (904,380)	$ 177,993	$ (1,044,942)
Basic weighted average common shares outstanding		393,818,282	372,908,767	390,423,083	369,418,037
Dilutive impact of assumed exercise or conversion of:
Diluted weighted average common shares outstanding		393,818,282	372,908,767	410,986,802	369,418,037
Diluted (loss) earnings per share	[1]	$ (0.28)	$ (2.43)	$ 0.43	$ (2.83)
Convertible Senior Note 1 [Member]
Dilutive impact of assumed exercise or conversion of:
Diluted weighted average common shares outstanding				12,454,620
Redeemable Noncontrolling Interest [Member]
Dilutive impact of assumed exercise or conversion of:
Diluted weighted average common shares outstanding				4,528,898
Stock Option 1 [Member]
Dilutive impact of assumed exercise or conversion of:
Diluted weighted average common shares outstanding				745,700
Other Securities [Member]
Dilutive impact of assumed exercise or conversion of:
Diluted weighted average common shares outstanding				2,834,501
[1]	In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive

Acquisitions - Summary of Conso

Acquisitions - Summary of Consolidated Balance Sheet Impact at Acquisition of Company's Business Combinations (Details) - CAD ($) $ in Thousands	Jun. 22, 2021	Apr. 01, 2021	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Goodwill			$ 1,988,250	$ 1,889,354	$ 1,954,471
Ace Valley
Business Acquisition [Line Items]
Cash and cash equivalents			1,544
Inventory			878
Other current assets			2,249
Property, plant and equipment			105
Goodwill			39,152
Accounts payable and other accrued expenses and liabilities			(1,724)
Deferred income tax liabilities			(1,899)
Net assets acquired			54,305
Consideration paid in cash			51,836
Other consideration			2,469
Total consideration		$ 51,836	54,305
Less: Cash and cash equivalents acquired			(1,544)
Net cash outflow (inflow)			50,292
Ace Valley | Brands
Business Acquisition [Line Items]
Intangible assets			14,000
Supreme Cannabis [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			41,306
Inventory			33,426
Other current assets			15,145
Property, plant and equipment			187,407
Goodwill			66,524
Accounts payable and other accrued expenses and liabilities			(13,056)
Debt and other liabilities			(88,324)
Deferred income tax liabilities			(3,260)
Net assets acquired			279,668
Consideration paid in cash	$ 84		$ 84
Consideration paid in shares			260,668
Replacement options	$ 140,159		$ 629
Replacement warrants			13,350
Other consideration			4,937
Total consideration			279,668
Less: Cash and cash equivalents acquired			(41,306)
Net cash outflow (inflow)			(41,222)
Supreme Cannabis [Member] | Brands
Business Acquisition [Line Items]
Intangible assets			24,600
Supreme Cannabis [Member] | Distribution Channel
Business Acquisition [Line Items]
Intangible assets			3,500
Supreme Cannabis [Member] | Operating Licenses
Business Acquisition [Line Items]
Intangible assets			12,400
Other
Business Acquisition [Line Items]
Cash and cash equivalents			1,227
Inventory			428
Other current assets			305
Property, plant and equipment			1,510
Goodwill			7,263
Debt and other liabilities			(1,037)
Deferred income tax liabilities			(540)
Net assets acquired			11,156
Consideration paid in cash			$ 7,104
Consideration paid in shares			4,052
Total consideration			$ 11,156
Less: Cash and cash equivalents acquired			(1,227)
Net cash outflow (inflow)			5,877
Other | Operating Licenses
Business Acquisition [Line Items]
Intangible assets			2,000
Two Thousand And Twenty Acquisitions
Business Acquisition [Line Items]
Cash and cash equivalents			44,077
Inventory			34,732
Other current assets			17,699
Property, plant and equipment			189,022
Goodwill			112,939
Accounts payable and other accrued expenses and liabilities			(14,780)
Debt and other liabilities			(89,361)
Deferred income tax liabilities			(5,699)
Net assets acquired			345,129
Consideration paid in cash			$ 59,024
Consideration paid in shares			264,720
Replacement options			$ 629
Replacement warrants			13,350
Other consideration			7,406
Total consideration			345,129
Less: Cash and cash equivalents acquired			(44,077)
Net cash outflow (inflow)			14,947
Two Thousand And Twenty Acquisitions | Brands
Business Acquisition [Line Items]
Intangible assets			38,600
Two Thousand And Twenty Acquisitions | Distribution Channel
Business Acquisition [Line Items]
Intangible assets			3,500
Two Thousand And Twenty Acquisitions | Operating Licenses
Business Acquisition [Line Items]
Intangible assets			$ 14,400

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details)	Dec. 31, 2021CAD ($)
C3
Business Acquisition [Line Items]
Goodwill expected to be deductible for income tax purposes	$ 0

Acquisitions - Ace Valley - Add

Acquisitions - Ace Valley - Additional Information (Details) - Ace Valley - CAD ($) $ in Thousands	Apr. 01, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Business acquisition, acquisition date	Apr. 1, 2021
Percentage of outstanding shares purchased	100.00%
Business acquisition, total purchase consideration	$ 51,836	$ 54,305
Business Combination, Contingent Consideration, Liability	$ 2,469

Acquisitions - Supreme Cannabis

Acquisitions - Supreme Cannabis - Additional Information (Details) - Supreme Cannabis [Member] $ in Thousands	Jun. 22, 2021CAD ($)Instrumentshares	Dec. 31, 2021CAD ($)
Business Acquisition [Line Items]
Name of acquiree		Supreme Cannabis
Date of acquisition	Jun. 22, 2021
Percentage of outstanding shares purchased	100.00%
Number of shares | shares	9,013,400
Shares issued, value	$ 260,668
Consideration paid in cash	84	$ 84
Replacement options	140,159	$ 629
Fair value of outstanding warrant	13,350
Fair value of replacement options	1,452
Fair value of replacement options included as consideration paid	629
Fair value of replacement options recognized as share-based compensation expense	823
Debentures Subject to Mandatory Redemption
Business Acquisition [Line Items]
Principal amount of convertible debt	$ 27,045
Number of shares convertible | Instrument	94,895,649
Share exchange ratio	0.011659
Debt Instrument, Fair Value Disclosure	$ 36,593
Conversion feature of debt	4,937
Debt component	$ 31,656
Warrant
Business Acquisition [Line Items]
Number of shares | shares	1,265,742

Acreage Arrangement and Amend_2

Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants - Additional Information (Details) $ / shares in Units, $ / shares in Units, $ in Thousands	Sep. 23, 2020CAD ($)	Sep. 23, 2020USD ($)$ / shares	Dec. 31, 2021CAD ($)shares	Dec. 31, 2020CAD ($)	Dec. 31, 2021CAD ($)shares	Dec. 31, 2021USD ($)	Dec. 31, 2020CAD ($)	Mar. 31, 2021CAD ($)	Jun. 24, 2020shares	Apr. 18, 2019$ / sharesshares
Business Acquisition [Line Items]
Debentures bear interest rate per annum			6.10%		6.10%
Warrant expiration date										Nov. 1, 2023
Estimated fair value			$ (67,282,000)	$ 193,998,000	$ (578,084,000)		$ 93,455,000
Tranche A Warrants
Business Acquisition [Line Items]
Warrants to acquire shares | shares										88,500,000
Exercise price of warrants | $ / shares										$ 50.40
Tranche B Warrants
Business Acquisition [Line Items]
Warrants to acquire shares | shares										38,500,000
Exercise price of warrants | $ / shares										$ 76.68
Tranche C Warrants
Business Acquisition [Line Items]
Warrants to acquire shares | shares										12,800,000
Tranche B and C Warrants | Second Amended and Restated Investor Rights Agreement and Consent Agreement
Business Acquisition [Line Items]
Number of common stock shares to be repurchased to avoid providing repurchase credit | shares			27,378,866		27,378,866
Value of common stock to be repurchased to avoid providing repurchase credit			$ 1,583,000,000		$ 1,583,000,000
Derivative liability			0		0
Debenture
Business Acquisition [Line Items]
Payments to acquire investments					66,995,000	$ 50,000
Debt Instrument, Fair Value Disclosure	$ 27,801,000							$ 27,448,000
Additional payment upon satisfaction of certain conditions						$ 50,000
Warrant
Business Acquisition [Line Items]
Derivative, financial liability			37,491,000		37,491,000			615,575,000
Estimated fair value			67,282,000	193,998,000	578,084,000		93,455,000
Maximum [Member] | Second Amended and Restated Investor Rights Agreement and Consent Agreement
Business Acquisition [Line Items]
Share repurchase credit limit			1,583,000,000		1,583,000,000
Acreage
Business Acquisition [Line Items]
Aggregate payment	$ 49,849,000	$ 37,500
Gain (Loss) on derivative, Net			59,000,000	$ (303,000,000)	497,000,000		$ (249,849,000)
Acreage | Acreage Financial Instrument
Business Acquisition [Line Items]
Derivative, financial liability			$ 103,000,000		$ 103,000,000			$ 600,000,000
Acreage | Maximum [Member]
Business Acquisition [Line Items]
Number Of Fixed And Floating Shares Issued | shares									32,700,000
Acreage | Class E Subordinated Voting Shares | Fixed Shares
Business Acquisition [Line Items]
Common stock shares conversion ratio	0.3048	0.3048
Acreage | Class D Subordinated Voting Shares | Floating Shares
Business Acquisition [Line Items]
Minimum call price | $ / shares		$ 6.41

Segment Information - Additiona

Segment Information - Additional Information (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2021Customer	Dec. 31, 2020Customer	Dec. 31, 2021SegmentCustomer	Dec. 31, 2020Customer
Segment Reporting Information [Line Items]
Number of operating segments | Segment			2
Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration Risk Customer Number Of Customers | Customer	0	1	1	1

Segment Information - Summary o

Segment Information - Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Net revenue	$ 140,972	$ 152,528	$ 408,555	$ 398,210
Gross margin	10,090	24,585	(33,812)	57,160
Selling, general and administrative expenses	116,835	144,078	355,165	426,723
Share-based compensation	6,777	19,963	35,856	72,632
Expected credit losses on financial assets and related charges		13,735		108,480
Asset impairment and restructuring costs	36,439	400,422	128,198	459,579
Operating loss	(149,961)	(553,613)	(553,031)	(1,010,254)
Loss from equity method investments		(671)	(100)	(40,851)
Other income (expense), net	34,282	(290,567)	810,769	(21,106)
(Loss) income before income taxes	(115,679)	(844,851)	257,638	(1,072,211)
Global Cannabis
Segment Reporting Information [Line Items]
Net revenue	82,977	103,828	271,241	277,404
Gross margin	(11,209)	7,394	(80,432)	12,598
Other Consumer Products
Segment Reporting Information [Line Items]
Net revenue	57,995	48,700	137,314	120,806
Gross margin	$ 21,299	$ 17,191	$ 46,620	$ 44,562

Segment Information - Summary_2

Segment Information - Summary of Disaggregation of Net Revenue by Geographic Area (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 140,972	$ 152,528	$ 408,555	$ 398,210
C A
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	78,644	91,060	241,440	243,084
Germany
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	23,143	31,262	71,619	87,649
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	22,764	18,141	60,856	40,885
Other
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 16,421	$ 12,065	$ 34,640	$ 26,592

Segment Information - Summary_3

Segment Information - Summary of Disaggregation of Long-lived Tangible Assets by Geographic Areas (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 1,080,179	$ 1,074,537
C A
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	876,331	847,678
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	140,299	143,747
Other
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 63,549	$ 83,112

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Jan. 31, 2022 - Subsequent Event € in Thousands, $ in Thousands	CAD ($)	EUR (€)
Subsequent Event [Line Items]
Proceeds from Divestiture of Businesses	$ 128,316	€ 88,698
Earnout Payment Receivable		€ 42,600